Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL & PROPRIETARY  
 
Page 1 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021  
 
 
 
Clinical Study Protocol  
 
A Phase 1/2, Open -label, Single -arm Study to A ssess 
the Safety , Tolerability , and Efficacy  of ST-400 
Autologous Hematopoietic Stem Cell Transplant for 
Treatment of Transfusion -dependent -thalassemia  
(TDT) 
 
 
 
 
 
 
Protocol Number:  ST-400-01 
BB-IND: BB-IND-17658 
Sponsor:  Sangamo Therapeutics, Inc.  
7000 Marina B oulevard  
Brisbane, CA 94005  
  

Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL & PROPRIETARY  
 
Page 2 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 Clinical Study Protocol  
 
A Phase 1/2, Open -label, Single -arm Study to Assess the 
Safety, Tolerability , and Efficacy  of ST-400 Autologous 
Hematopoietic Stem Cell Transplant for Treatment of 
Transfusion -dependent -thalassemia  (TDT) 
 
 
Protocol Number:  ST-400-01 
BB-IND: BB-IND-17658 
Sponsor:  Sangamo Therapeutics , Inc. 
7000 Marina Boulevard  
Brisbane, CA 94005  
Indication:  Transfusion -dependent β-thalassemia  (TDT) 
Development Phase:  Phase 1/2  
Study Duration:  Up to 182 weeks (3.5 years)  
Study Design: Open-label, single -arm 
Number of Subjects : 6 
Medical Monitor:  
 Didier Rouy, MD, PhD  
Senior Medical Director, Clinical Sciences  
Sangamo Therapeutics, Inc.  
Phone: (628) 252 -7504 
Fax: (510) 970 -6009 
drouy@sangamo.com  
 
Date of Original Version: August 15, 2017 
Amendment 1:  June 28, 2018  
Amendment 2:  October 10, 2018 
Amendment 3:  February 22, 2019  
Amendment 4:  March 10, 2020 
Amendment 5:  April 09, 2021 
 
PROPERTY OF SANGAMO THERAPEUTICS , INC. 
Confidential  and Proprietary  
This document contains confidential and proprietary information. It is intended solely for the use 
of the Investigator , co-Investigator s, staff, appropriate institutional review boards or ethical 
committees, and other required  regulatory bodies.  The information in this document may not be 
disclosed, divulged , or published externally without written approval from Sangamo 
Therapeutics , Inc. 
This study will be conducted according to the princi ples of Good Clinical Practice  and in 
accordance with the U.S. Code of Federal Regulations and the International Conference on 
Harmonization  Guidelines.  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 3 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021  
 
 
 
 
Clinical Approval Signature Page  
 
 
 
Protocol Number:  ST-400-01 
Protocol Title:  A Phase 1/2, Open -label, Single -arm Study to 
Assess the Safety, Tolerability, and Efficacy of 
ST-400 Autologous Hematopoietic Stem Cell 
Transplant for Treatment of Transfusion -
dependent -thalassemia (TDT)  
 
 
 
 
 
 
 
  
___________________________________  ________________  
Didier Rouy, M.D., Ph.D.  Date 
Medical Monitor  
Sr. Medical Director , Clinical Sciences  
Sangamo Therapeutics, Inc.   
  
09APR2021Sanggm~ 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 4 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021  
 
 
 
 
Investigator Agreement  Page 
 
 
 
Protocol Number:  ST-400-01 
BB-IND: BB-IND-17658 
Protocol Title:  A Phase 1/2, Open -label, Single -arm Study to 
Assess the Safety, Tolerability, and Efficacy of 
ST-400 Autologous Hematopoietic Stem Cell 
Transplant for Treatment of Transfusion -
dependent -thalassemia (TDT)  
 
 
I have read all pages o f this clinical study protocol for which Sangamo Therapeutics, Inc. is the 
Sponsor. I agree to conduct the study as outlined in the protocol , and to comply with all terms and 
conditions set out therein. I confirm that I will conduct the study in accordance  with ICH guidelines 
and applicable local regulations. I will ensure that sub -Investigator (s) and other relevant members 
of my staff have access to cop ies of this protocol and the ICH  guidelines to enable them to work 
in accordance with the provisions of t hese documents.  
 
 
___________________________________  ________________  
Investigator Signature          Date 
 
 
___________________________________   
Investigator Printed Name          
 
 
___________________________________   
Site Name            
 
 
________________________________ _____________________________________ ___  
Site Address  
  

Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 5 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 TABLE OF CONTENTS  
TABLE OF CONTENTS  ................................ ................................ ................................ ............. 5 
LIST OF FIGURES  ................................ ................................ ................................ ......................  9 
LIST OF TABLES  ................................ ................................ ................................ ........................  9 
SYNOPSIS  ................................ ................................ ................................ ................................ ... 10 
ABBREVIATIONS  ................................ ................................ ................................ .....................  17 
1. INTRODUCTION ................................ ................................ ................................ ........... 19 
1.1 β-thalassemia  ................................ ................................ ................................ ........ 19 
1.2 Fetal Hemogl obin................................ ................................ ................................ .. 20 
1.3 BCL11A in Hemoglobin Regulation  ................................ ................................ .... 20 
1.4 Sangamo Zinc Finger Nucleases for Therapeutic Genome Editing  ......................  21 
1.5 Clinical Rationale for ST -400 Mechanism of Action  ................................ ........... 22 
1.6 Preclinical Pharmacology Studies ................................ ................................ ......... 23 
1.6.1  In Vitro Studies ................................ ................................ ................................ ..... 23 
1.6.1.1  In Vitro Erythropoiesis  ................................ ................................ ..........................  24 
1.6.1.2  Colony-forming Unit (CFU) Potential  ................................ ................................ .. 24 
1.6.1.3  Comparison of the Original and Optimized ZFN Pairs  ................................ ........ 24 
1.6.2  In Vivo Studies ................................ ................................ ................................ ...... 24 
1.7 Clinical Studies  ................................ ................................ ................................ ..... 25 
1.8 Targeted Patient Population  ................................ ................................ ..................  25 
1.9 Risk Benefit Assessment ................................ ................................ .......................  25 
1.9.1  Assessment of Risk  ................................ ................................ ...............................  25 
1.9.1.1  Previous Experience with ZFNs in Humans  ................................ .........................  26 
1.9.1.2  In Vitro Studies ................................ ................................ ................................ ..... 26 
1.9.1.3  In Vivo Studies ................................ ................................ ................................ ...... 28 
1.9.2  Assessment of Benefit ................................ ................................ ...........................  29 
2. STUDY OBJECTIVES  ................................ ................................ ................................ ... 30 
2.1 Primary Objective  ................................ ................................ ................................ . 30 
2.2 Secondary Objective  ................................ ................................ .............................  30 
2.3 Exploratory Objectives  ................................ ................................ .........................  30 
3. STUDY OUTCOME MEASURES  ................................ ................................ ................  31 
3.1 Primary Outcome Measures  ................................ ................................ ..................  31 
3.2 Secondary Outcome Measures  ................................ ................................ .............. 31 
3.3 Exploratory Outcome Measures  ................................ ................................ ........... 31 
4. STUDY DESIGN  ................................ ................................ ................................ ............. 32 
4.1 Overview  ................................ ................................ ................................ ............... 32 
4.2 Justification of  Study Design  ................................ ................................ ................  32 
4.3 Number of Subjects ................................ ................................ ...............................  32 
4.4 Dose and Dose Justification  ................................ ................................ ..................  32 
4.5 Study Duration  ................................ ................................ ................................ ...... 33 
4.6 Visit Schedule  ................................ ................................ ................................ ....... 33 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 6 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 4.7 Study Procedures  ................................ ................................ ................................ .. 33 
4.8 Study Suspension Rules  ................................ ................................ ........................  36 
4.9 Study Stopping Rules  ................................ ................................ ............................  37 
5. SUBJECT SELECTION  ................................ ................................ ................................  38 
5.1 Inclusion Criteria  ................................ ................................ ................................ .. 38 
5.2 Exclusion Criteria  ................................ ................................ ................................ . 38 
6. INFORME D CONSENT  ................................ ................................ ................................  40 
7. STUDY METHODOLOGY  ................................ ................................ ...........................  41 
7.1 Screening Visits ................................ ................................ ................................ .... 41 
7.2 Subject Enrollment ................................ ................................ ................................  42 
7.3 Mobilization, Apheresis, and Conditioning  ................................ ..........................  42 
7.3.1  CD34+ HSPC Apheresis  ................................ ................................ .......................  42 
7.3.1.1  G-CSF and Plerixafor Mobilization and Apheresis  ................................ .............. 42 
7.4 Gamete and Embryo Cryopreservation  ................................ ................................ . 43 
7.5 Baseline Assessments  ................................ ................................ ...........................  44 
7.6 Conditioning  ................................ ................................ ................................ ......... 45 
7.7 Day 0 (ST -400 Infusion)  ................................ ................................ .......................  46 
7.8 Days 7 (+/ -1 day), 14 (+/ -1 day), 21 (+/ -1 day), 28 (+/ -1 day), 35 (+/ - 2 days), 42 
(+/-2 days), 56 (+/ -5 days), a nd 90 (+/ -7 days); and Weeks 26, 39, and 52 (+/ - 14 
days) (Primary Study Period) ................................ ................................ ................  46 
7.9 Weeks 65, 78, 91, 104, 117, 130, 143, and 15 6 (+/- 14 days) (Follow -up Study 
Period) ................................ ................................ ................................ ...................  48 
7.10  Early Termination Visit  ................................ ................................ ........................  48 
7.11  Rescue Treatment ................................ ................................ ................................ .. 49 
7.12  Unscheduled Visits  ................................ ................................ ...............................  50 
7.13  Subject Withdrawal and Discontinuation from Study  ................................ .......... 50 
7.14  Long-term Follow -up Protocol for Adverse Effects of Gene Therapy  .................  50 
8. STUDY PRODUCT AND OTHER MEDICATIONS  ................................ .................  51 
8.1 ST-400................................ ................................ ................................ ...................  51 
8.1.1  Inventory, Storage, and Handling  ................................ ................................ ......... 51 
8.1.2  Administration  ................................ ................................ ................................ ...... 51 
8.1.3  Precautions ................................ ................................ ................................ ............ 52 
8.2 Intravenous Busulfan  ................................ ................................ ............................  52 
8.2.1  Inventory, Storage, and Handling  ................................ ................................ ......... 52 
8.2.2  Administration  ................................ ................................ ................................ ...... 52 
8.2.3  Precautions  ................................ ................................ ................................ ............ 52 
8.3 G-CSF ................................ ................................ ................................ ...................  52 
8.3.1  Inventory, Storage , and Handling  ................................ ................................ ......... 53 
8.3.2  Administration  ................................ ................................ ................................ ...... 53 
8.3.3  Precautions  ................................ ................................ ................................ ............ 53 
8.4 Plerixafor ................................ ................................ ................................ ............... 53 
8.4.1  Inventory, Storage, and Handling  ................................ ................................ ......... 53 
8.4.2  Administration  ................................ ................................ ................................ ...... 53 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 7 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 8.4.3  Precautions  ................................ ................................ ................................ ............ 53 
8.5 Concomitant Medication and Supportive Care  ................................ .....................  53 
8.6 Prohibited Medications  ................................ ................................ .........................  54 
9. STUDY ASSESSMENTS  ................................ ................................ ...............................  55 
9.1 Medical History  ................................ ................................ ................................ .... 55 
9.2 Demographics  ................................ ................................ ................................ ....... 55 
9.3 Concomitant Medications  ................................ ................................ .....................  55 
9.4 Transfusion History  ................................ ................................ ..............................  55 
9.5 Physical Exam  ................................ ................................ ................................ ....... 55 
9.6 Vital Signs  ................................ ................................ ................................ ............. 55 
9.7 Karnofsky Perf ormance Scale ................................ ................................ ............... 55 
9.8 Pregnancy Test  ................................ ................................ ................................ ...... 55 
9.9 Pulmonary Function Tests (PFTs)  ................................ ................................ ........ 56 
9.10  Chest X-ray ................................ ................................ ................................ ........... 56 
9.11  Infectious Disease Panel  ................................ ................................ .......................  56 
9.12  Clinical Labs  ................................ ................................ ................................ ......... 56 
9.13  Electrocardiogram (ECG)  ................................ ................................ .....................  57 
9.14  Liver Biopsy ................................ ................................ ................................ .......... 57 
9.15  Comprehensive Hemoglobin Analysis ................................ ................................ . 57 
9.16  Screening for Potential Hematological Malignancies  ................................ ........... 57 
9.17  BCL11A Gene Modification Assay  ................................ ................................ ...... 58 
9.18  Subset Analysis of BCL11A G ene Modification ................................ ..................  59 
9.19  Sampling for Potential Retrospective Analysis in the Event of Hematological 
Malignancy  ................................ ................................ ................................ ........... 59 
9.20  HbF Quantification  ................................ ................................ ...............................  59 
9.21  Immunological Assays  ................................ ................................ ..........................  59 
9.22  Transfusion Log  ................................ ................................ ................................ .... 59 
9.23  Thalassemia -related Disease Biomarkers  ................................ .............................  60 
9.24  Endocrine Lab Testing  ................................ ................................ ..........................  60 
9.25  Echocardiogram (ECHO)  ................................ ................................ ......................  60 
9.26  Liver MRI  ................................ ................................ ................................ ............. 60 
9.27  Cardiac MRI ................................ ................................ ................................ .......... 60 
9.28  DXA ................................ ................................ ................................ ......................  60 
9.29  SF-36 Survey  ................................ ................................ ................................ ........ 60 
9.30  Bone Marrow Aspiration  ................................ ................................ ......................  61 
9.31  Percentage of F -cells ................................ ................................ .............................  61 
10. ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  ................................ ..... 62 
10.1  Definitions of an Adverse Event  ................................ ................................ ........... 62 
10.2  Classification of an Adverse Event  ................................ ................................ ....... 62 
10.2.1  Definition of a Serious Adverse Event  ................................ ................................ . 62 
10.2.2  Determination of Relationship of Adverse Event to Study Treatment  .................  63 
10.2.3  Determination of Severity of Adverse Event  ................................ ........................  64 
10.2.4  Determination of Expectedness of Adverse Event  ................................ ............... 64 
10.3  Adverse Event Reporting  ................................ ................................ ......................  64 
10.4  Serious Adverse Event Reporting  ................................ ................................ ......... 64 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 8 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 10.5  Specific Serious Adverse Events  ................................ ................................ .......... 65 
10.6  Suspected Unexpected Serious Adverse Reactions  ................................ .............. 65 
11. PROCEDURES FOR HANDLING SPECIAL SITUATIONS  ................................ .. 66 
11.1  Pregnancy and Contraception Requirements  ................................ ........................  66 
11.2  Medical Emergency  ................................ ................................ ..............................  67 
12. SAFETY MONITORING  ................................ ................................ ..............................  68 
13. STATISTICAL ANALYSIS  ................................ ................................ ..........................  69 
13.1  Analysis Populations  ................................ ................................ .............................  69 
13.2  Methods of Analysis  ................................ ................................ .............................  69 
13.3  Analysis of Primary Outcome Measures  ................................ ..............................  69 
13.4  Analysis of Secondary Outcome Measures  ................................ ..........................  69 
13.5  Analysis of Exploratory Outcome Measures  ................................ ........................  69 
13.6  Other Study Data ................................ ................................ ................................ ... 70 
13.7  Sample Size  ................................ ................................ ................................ ........... 70 
13.8  Interim Analysis  ................................ ................................ ................................ .... 70 
14. INVESTIGATOR OBLIGATIONS  ................................ ................................ .............. 71 
14.1  Informed Consent ................................ ................................ ................................ .. 71 
14.2  Future Use of Stored Specimens  ................................ ................................ ........... 71 
14.3  Institutional Review Board and BioSafety Committee  ................................ ......... 71 
14.4  Protocol Amendments  ................................ ................................ ...........................  71 
14.5  Subject Privacy  ................................ ................................ ................................ ..... 71 
14.6  Other Reporting Obligations  ................................ ................................ .................  72 
15. ADMINISTRATIVE CONSIDERATIONS  ................................ ................................ . 73 
15.1  Study Documentation ................................ ................................ ............................  73 
15.2  Record Retention  ................................ ................................ ................................ .. 73 
15.3  Case Report Forms  ................................ ................................ ................................  73 
15.4  Termination of the Study  ................................ ................................ ......................  73 
15.5  Study Monitoring  ................................ ................................ ................................ .. 74 
15.6  Confidential Information and Publication  ................................ ............................  74 
15.7  Study Funding  ................................ ................................ ................................ ....... 75 
16. REFERENCES  ................................ ................................ ................................ ................  76 
APPENDIX 1: SCHEDULE OF EVENTS  ................................ ................................ ............... 79 
APPENDIX 2: -GLOBIN ALLELLIC VARIANTS ASSOCIATED WITH CLINICALLY 
SIGNIFICANTLY ALTERED OXYGEN AFFINITY  ................................ ............... 82 
 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 9 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 LIST OF FIGURES  
 
FIGURE 1: REGULATION OF HEMOGLOBIN SWITCHING BY BCL11A ................................ ........ 21 
FIGURE 2: GENE MODIFICATION OF BCL11A  ERYTHROID ENHANCER BY SANGAMO ZFNS .. 22 
FIGURE 3: ST-400 TREATMENT  ................................ ................................ ..............................  23 
FIGURE 4: SCHEMA OF STUDY VISITS ................................ ................................ .....................  33 
FIGURE 5: SCHEMA OF MOBILIZATION AND APHERESIS ................................ .........................  34 
FIGURE 6: SCHEMA OF SUBJECT ENROLLMENT  ................................ ................................ ....... 36 
 
LIST OF TABLES  
 
TABLE 1: CLINICAL LABORATORY TESTS ................................ ................................ .............. 57 
 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 10 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 SYNOPSIS  
Title A Phase 1/2, Open -label, Single -arm Study to Asses s the Safety, Tolerability, 
and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for 
Treatment of Transfusion -dependent -thalassemia (TDT)  
Sponsor Sangamo Therapeutics, Inc.  
Investigational 
Product ST-400 is composed of autologous CD34+ hematopoietic stem/progenitor 
cells (HSPCs)  that are genetically modified ex vivo at the erythroid -specific 
enhancer of the BCL11A gene by Zinc Finger Nuclease (ZFN ) mRNAs 
SB-mRENH1 and SB -mRENH2  to boost endogenous production of fetal 
hemoglobin (HbF ). 
Objectives  Primary Objective   
The primary objective of this study is to evaluate the safety and tolerability of 
ST-400 in patients with TDT. 
Secondary Objective  
The secondary objective of this study is to assess the efficacy of ST -400 in 
patients with TDT. 
Exploratory Objectives  
The exploratory objectives of this study are to:  
• Evaluate the gene modification characteristics (% and durability) at the 
erythroid-specific enhancer of the BCL11A gene after ST -400 treatment.  
• Assess the impact of ST-400 on the biochemical, imaging, functional, and 
bone marrow evaluations related to β-thalassemia and HSCT.  
Outcome 
Measures  Primary Outcome Measure s  
Safety and tolerability will be assessed by incidence of adverse events (AEs) 
and serious AEs (SAEs).  Additional safety evaluations will include:  
• Routine hematology and chemistry laboratory testing, vital signs, physical 
exam, electrocardiogram ( ECG), echocardiogram (ECHO), pulmonary 
function tests (PFTs), bone marrow aspiration, and concomitant 
medicatio ns. 
• Kinetics and success of hematopoietic reconstitution.  
• Duration of hospitalization after conditioning . 
• Screening for potential development of hematological malignanc ies. 
Secondary  Outcome Measure s 
Change from baseline will be assessed by: 
• Clinical laboratory measurement of Hb fractions (A and F in g/dL) and 
percent HbF . 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 11 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 • Calculation of annualized frequency and volume of packed red blood cell 
(PRBC) transfusions  after ST-400 infusion as compared to baseline 
transfusion support in the 2 years prior to screening . 
Exploratory  Outcome Measure s 
To assess the following:  
• Percentage  and durability  of gene modification at the erythroid -specific 
enhancer (ESE) of the BCL11A genes 
• Change from baseline in  
o thalassemia -related disease biomarkers . 
o endocrine function by lab testing.  
o cardiac function by ECHO . 
o iron content by MRI (liver and heart). 
o bone mineral density by dual-energy X-ray absorptiometry  (DXA). 
o quality-of-life by Short Form Health Status Survey (SF -36 Survey). 
o overall function by Karnofsky performance score . 
o Percentage of F -cells 
• Efficiency of apheresis procedure.  
• Difference between % indels in ST -400 product and indels detected in 
bone marrow and blood following ST -400 infusion.  
Study 
Population  Male or female subjects with TDT who are 18 years to 40 years of age, 
inclusive, and who are willing and able to undergo autologous  hematopoietic 
stem cell transplantation (HSCT).  
Inclusion & 
Exclusion 
Criteria Inclusion Criteria  
1. Signed informed consent form . 
2. Male or female between 18 and 40 years of age, inclusive . 
3. Clinical diagnosis of TDT with >8 documented RBC transfusion  events 
per year on an annualized basis in the 2 -years prior to Screening. 
4. Confirmed −thalassemia diagnosis by molecular genetic testing. 
5. Clinically stable and eligible to undergo HSCT. 
6. Able and w illing to use an effective method of  contracepti on 
(Section 11.1) from the signing of the informed consent through the 
Primary Study Period , for male and  female subjects with reproductive  
potential. 
Exclusion Criteria  
1. Previous history of autologous or allogeneic HSCT or solid organ 
transplantation . 
2. Pregnant or breastfeeding female . 
3. -globin allelic variants associated with clinically significant altered 
oxygen affinity (see Appendix 2 ). 
4. Medical contraindication to  mobilization , apheresis or conditioning . 
5. Absolute neutrophil count (ANC) ≤1,000/µL . 
6. Abnormal liver function tests defined by:  
• direct bilirubin ≥ 3x ULN, or  
• AST or ALT ≥3x ULN  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 12 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 7. Renal dysfunction as defined by serum creatinine ≥2.0 mg/dL . 
8. Bridging fibrosis, liver cirrhosis, or active hepatitis based on liver biopsy 
obtained in previous 12 months or at S creening. 
9. Massive splenomegaly  (based on Investigator ’s judgement) . 
10. Treatment wit h prohibited medications in previous  30 days  
11. Clinically significant, active bacterial, viral, fungal, or parasitic infection  
(based on Investigator ’s judgement).  
12. Diagnosis of HIV or evidence of active HBV or HCV infection based on 
Screening laboratory testing.  
13. Karnofsky performance scale ≤6 0. 
14. Corrected DLCO ≤5 0% of predicted or clinically -significant restrictive 
lung disease based on Screening pulmonary function tests (PFTs).  
15. Congestive heart failure (NYHA Class III or IV), unstable angi na, 
uncontrolled arrhythmia, or left ventricular ejecti on fraction  (LVEF) 
<40%. 
16. QTcF >500 msec based on S creening ECG . 
17. Cardiac T2* MRI <10 msec based on S creening MRI . 
18. History of significant bleeding disorder . 
19. Current diagnosis  of uncontrolled seizures . 
20. History of active malignancy in past 5 years (non -melanoma skin cancer 
or cervical cancer in situ permitted) , any history of hematologic 
malignancy, or family history of cancer predisposition syndrome without 
negative testing result in the study candidate . 
21. History of or active alcohol or substance abuse that in the opinion of the 
Investigator  may interfere with study compliance . 
22. History of therapeutic non -adherence . 
23. Currently participating in another clinical trial using an investigational 
study medication, or participation in such a trial within 90 days or less 
than 5 half -lives of the in vestigational product prior to S creening visit . 
24. Previous treatment with gene therapy . 
25. Allergy or hypersensitivity to busulfan or study drug excipients (human 
serum albumin, DMSO, and Dextran 40) . 
26. Any other reason that, in the opinion of the Investigator or Medical 
Monitor, would render the subject unsuitable for participation in the study . 
Study Design  This is a Phase 1/2, open -label, multi -center, single -arm study conducted in 
six (6) subjects with a diagnosis of TDT.  
Eligible subjects will be enrolled and undergo apheresis to collect autologous 
CD34+ HSPCs. The CD34+ HSPCs will be treated ex vivo by transfection 
with ZFN mRNAs SB -mRENH1 and SB -mRENH2 to manufacture the study 
drug, ST-400. Subjects will receive conditioning  therapy with intravenous 
(IV) busulfan before being infused with ST -400.  
Clinical and laboratory data will be collecte d for a total of 15 6 weeks 
post-infusion of ST -400. 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 13 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 Treatment 
Plan CD34+ HSPCs will be mobilized in  each subject using treatment with G-CSF 
and plerixafor.  Mobilized CD34+ HSPCs  will be collected from each subject 
on Days 5 and 6 (+Day 7 if needed to secure the rescue treatment) of 
mobilization by apheresis . 
The collected cells of each subject will be split into 2 portions, one portion for 
ST-400 drug manufacturing and the other portion set aside in the event a 
rescue treatment  is indicated.  
The rescue treatment portion  must comprise  a minimum of 2.5 x 106 CD34+ 
HSPCs/kg . The rescue treatment portion  will be cryopreserved unmodified 
and stored at the study site for availability in the event of delayed 
hematopoietic reconstitution o r graft failure with aplasia . 
For subjects in whom the first apheresis cycle does not mobilize the minimum 
number of  CD34+ HSPCs required for ST -400 drug manufacturing and for 
rescue treatment, the mobilization procedure may be repeated at the discretion 
of the Investigator  based on the subject’s clinical status.  
The remainder of a subject’s mobilized and harvested cells will be purified 
for CD34+ HSPCs and undergo transfection  with ZFN mRNAs SB-mRENH1 
and SB-mRENH2  to disrupt the erythroid-specific enhance r of the BCL11A 
gene and  yield ST-400. ST-400 will be cryopreserved and stored until 
subsequent steps in the clinical protocol are completed and the subject is ready 
for ST-400 infusion.  
A subject will not proceed to conditioning  with IV busulfan  until a sufficient 
quantity of  rescue treatment is obtained and ST -400 is manufactured, passes 
quality control and release testing, and is confirmed as received at the clinical 
site. 
After release of  ST-400 for clinical use, subjects will be admitted to the 
hospital to begin IV busulfan in a dedicated transplant unit. Subjects will 
receive a myeloablative dose of busulfan  (3.2 mg/kg/day ; administered IV via 
central venous catheter  either once daily or  every 6 hours ) for 4 days (total 
dose of 12.8 mg/kg) . After the first dose, t he IV busulfan  dose will be adjusted 
based on pharmacokinetic s ampling to target a total area under the curve 
(AUC) of 16,000 -20,000 µmol*min. 
No sooner than 72 h ours after the final dose of IV busulfan  in the conditioning  
phase, subjects will be infused on Day 0 with ST -400. The minimum cell dose 
of ST-400 to be administered is 3.0 x 106 cells/kg. Subjects may receive more 
than one lot of ST -400 if multiple apheresis cycles were performed  to achieve 
the minimum cell dose. 
The first 3 subjects will be considered sentinel subjects and will be enrolled 
sequentially as follows: The first subject will be enrolled and receive ST -400 
infusion. T he second subject may proceed with  CD34+ HS PC mobilization 
and drug manufacturing at any time but shall not proceed to conditioning  or 
ST-400 administration until the first subject has  achieved successful 
hematopoietic reconstitution (defined as  ANC ≥500 cells/µL for 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 14 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 3 consecutive days and platelet count ≥20,000 cells/µL for 3 consecutive 
measurements  spanning a minimum of 3 calendar days  (in the absence of 
platelet transfusion in the preceding 7 days) . Similarly, the third subject may 
not proceed to conditioning  or ST-400 administration until the second  subject 
has achieved successful hematopoietic reconstitution. If unexpected toxicities  
are reported, enrollment and dosing will be paused pending review.  
After the 3 sentinel subjects have achieved successful hematopoieti c 
reconstitution,  all safety data from the study will be reviewed by the Safety 
Monitoring Committee (SMC) . See Section “12. Safety Monitoring ” for 
additional details . If no study suspension or stopping rules are met and no 
significant safety concerns related to ST -400 are reported, the subsequent 
3 subjects may receive ST -400 concurrently without waiting for other subjects 
to engraft.  
Should a s ubject experience delayed hematopoietic reconstitution or graft 
failure with aplasia  (defined as persistent  ANC <500 cells/µL through Day 42 
post-infusion), the subject  will receive the rescue treatment consisting of  
unmodified , autologous CD34+ HSPCs , and a S MC safety review will be 
performed . The rescue treatment may be administered  at any time  after 
ST-400 infusion  if needed at the discretion of the Investigator  based on 
clinical indications for subject safety. 
Study 
Duration  Duration of study participation will be up to 182 weeks for each subject, 
divided into 4  study segments:  
• Screening (up to 6 weeks)  
• Mobilization , Apheresis, Conditioning  (up to 20 weeks) 
• Primary Study P eriod (starting with ST-400 infusion on Day 0; 52 weeks) 
• Follow-up Study P eriod (104 weeks)  
Subjects will be hospitalized at the study center following IV busulfan 
conditioning and ST -400 infusion . In line with typical clinical practice, 
subjects may be discharged following primary hospitalization upon achievi ng 
(1) neutrophil recovery (defined per protocol as ANC ≥ 500 cells/µL on 3 
consecutive days) and (2) all other institutional criteria required for discharge 
following standard myeloablative autologous hematopoietic stem cell 
transplantation ( HSCT) (estimated 2 to 4 weeks; however, duration is variable 
depending on each subject’s clinical course) . Subjects  will be evaluated at the 
study center weekly until Day 42, then at Day s 56 and 90, and then every 
13 weeks until the final Week 156  visit (see Appendix 1 ).  Each subject will 
thus have a total of 3 years of monitoring following ST -400 infusion.  
To assess long -term safety, subjects will be asked to participate in a separate 
long-term follow -up (LTFU) study a fter they complete this study. The total 
combined (current and LTFU studies) follow up period will last 15 years.  
 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 15 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 Safety 
Monitoring  Safety and tolerability of ST -400 will be monitored throughout the study by 
assessing incidence of AEs/SAEs. Additional safety evaluations will include:  
• Routine hematology and chemistry laboratory testing, vital signs, physical 
exam, ECG, echocardiogram (ECHO), pulmonary function tests (PFTs), 
bone marrow aspiration, and concom itant medications.  
• Kinetics and success of hematopoietic reconstitution.  
• Duration of hosp italization after conditioning . 
• Screening for  potential development of hematological malignanc ies. 
During the conditioning  and immediate post -transplant period, subjec ts will 
be admitted to an inpatient transplant unit for treatment. Standard transplant 
medical care will be provided as per Investigator ’s judgement and study center 
practices. Additional safety precautions , assessments, and treatments 
conducted as part of  standard post -transplant medical care  outside of those 
specified in this study (e.g., clinical laboratory testing, immune function 
testing, CMV prophylaxis , G-CSF administration, etc.) will be undertaken as 
per Investigator ’s judgement and study center pr actice. All AEs, irrespective 
of whether they are related or not related to the apheresis, conditioning, or 
ST-400, will be assessed and reported.  
An external, independent SMC with appropriate medical and scientific 
expertise in TDT and HSCT will provide oversight of the study for patient 
safety. The SMC will be convened after the 3 sentinel subjects have achieved 
successful hematopoietic reconstitut ion based on the criteria defined, and 
subsequently approximately every 3 -6 months during the study period to 
monitor the safety and tolerability of ST -400.  
The SMC may be convened earlier or at any time if deemed necessary by the 
Sponsor or SMC. Specifically, the SMC will be convened if a study 
suspension rule is met. When convened, the SMC will evalua te all available 
data to provide recommendations on changes to the study and whether 
enrollment or dosing should continue.  The SMC will also provide 
recommendations on any ST-400-related AEs that should be characterized as 
dose-limiting toxicities of ST -400 treatment.  
Study 
Suspension 
Rules Study enrollment and dosing will be suspended pending SM C evaluation of 
clinical trial safety data if any of the following occurs :  
1. A subject develops a Gr ade 3 or higher AE assessed as related to ST-400 
by the Investigator  or Sponsor.  
2. A subject experiences  delayed hematopoietic reconstitution  or graft failure 
with aplasia requiring rescue treatment.  
3. A subject develops a malignancy (excluding non -melanoma skin cancer 
and cervical cancer in situ).  
4. A subject dies.  
5. The SMC and/or Sponsor determine that an event or current data warrant 
further evaluation by the SMC.  
Subjects who have already been dosed with ST -400 will continue to be 
followed for safety monitoring as part of the clinical trial.  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 16 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 Study 
Stopping 
Rules Study enrollment and dosing will be permanently discontinued if  any of the 
following occurs : 
1. Sponsor, in consultation with the SMC or Regulatory Agency, decides for 
any reason that subject safety may be compromised by continuing the 
study. 
2. A subject develops a  malignancy assessed as related to ST -400. 
3. Any other risk of ST-400 deemed medically unacceptable by the Sponsor 
is identified . 
4. Sponsor decides to discontinue the development of ST-400. 
Subjects who have already been dosed with ST -400 will continue to be 
followed for safety monitoring as part of the clinical trial.  
Sample Size  This study will enroll and treat a total of 5 to 6 subjects. Subjects who do not 
receive ST -400 or are lost to follow -up or withdraw from the study before the 
Week 26 visit in the Primary Study Period (beginning with ST -400 infusion) 
will be replaced . 
Statistical 
Analyses  Statistical analyses will primarily be descriptive, and no formal hypothesis 
testing will be conducted.  
 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 17 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 ABBREVIATIONS  
AE  adverse event/experience  
ALKP  alkaline phosphatase  
ALT  alanine aminotransferase (SGPT)  
ANC  absolute neutrophil count    
AST  aspartate aminotransferase (SGOT)  
AUC  area under the curve  
BSC  BioSafety Committee   
BUN  blood urea nitrogen 
CBC  complete blood count  
CCOA  Clinical Certificate of Analysis  
CFU  colony forming units  
CMV  cytomegalovirus  
COA  Certificate of Analysis  
CRF  case report form  
CTCAE  Common Terminology Criteria for Adverse Events  
DLCO  diffusing capacity for c arbon monoxide  
DMSO  dimethyl sulfoxide  
DNA  deoxyribonucleic acid  
DPT  day post-transfection  
DSB  double-strand break  
DXA  dual-energy X-ray absorptiometry  
ECG  electrocardiogram  
ECHO  echocardiogram  
ETV  early termination visit  
FDA  Food and Drug Administration  
G-CSF  granulocyte colony -stimulating factor  
GVHD  graft-versus-host disease  
HBV  hepatitis B virus 
Hb  hemoglobin  
HbF  fetal hemoglobin  (22) 
HCV  hepatitis C virus  
HIV  human immunodeficiency virus  
HLA   human leukocyte antigen  
HSCT  hematopoietic stem cell transplant ation 
HSPC  hematopoietic stem/progenitor cell  
ICF  informed consent form  
IEC  Independent Ethics Committee  
Indels  insertions and deletions  
IRB  institutional review board  
ITT  intent-to-treat 
IUD  intrauterine device  
IUS  intrauterine hormone -releasing system  
IV  intravenous  
IVIG  intravenous immunoglobulin  
kg  kilogram 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 18 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 LDH  lactate dehydrogenase  
LTFU  Long-Term Follow -Up 
LVEF  left ventricular ejection fraction  
MedDRA   Medical Dictionary fo r Regulatory Activities  
mL  milliliter 
MRI  magnetic resonance imaging  
mRNA  messenger RNA  
NYHA  New York Heart Association  
NIH  National Institutes of Health  
NSG  NOD/SCID/IL2rγnull  
PFT  pulmonary function test  
PRBC  packed red blood cell  
RBC  red blood cell  
RNA  ribonucleic acid  
SAR  serious adverse reaction  
SAE  serious adverse event  
SB-mRENH1  mRNA encoding the left optimized ZFN targeted to the BCL11A 
erythroid-specific enhancer  
SB-mRENH2   mRNA encoding the right optimized ZFN targeted to the BCL11A 
erythroid-specific enhancer   
SCD  sickle cell disease  
SCID  severe combined immunodeficiency  
SF-36  36-Item Short Form Health Status Survey  
SMC  Safety Monitoring Committ ee 
SMT                            Safety Monitoring Team  
SOE  Schedule of Events  
SUSAR  suspected unexpected serious adverse reaction  
TDT  transfusion -dependent β-thalassemia  
ULN  upper limit of normal  
UPLC  Ultra performance liquid chromatography  
VOD  veno-occlusive disease  
WBC  white blood cell  
ZFN  zinc finger nuclease  
ZFP  zinc finger protein   
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 19 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 1. INTRODUCTION  
1.1 β-thalassemia  
-thalassemia is an inherited anemia characterized by absent or defective β -globin chain synthesis  
(Higgs & Engel, 2012 ). The defect causes an imbalance in globin chain production , and a reduction 
in hemoglobin ( Hb; which is made up of two  α-globin and two  β-globin chains) . As a consequence  
of the globin chain imbalance , unstable α -globin chain tetramers form in red blood cells (RBCs) 
or RBC precursors , and intramedullary destruction, a poptosis, ineffective erythropoiesis, iron 
overload, and profound anemia  occur (Origa, 2017 ).  
Thalassemia is considered one of the most frequent genetic diseases in the world.  It is estimated 
that about 1.5% of the global populati on are carriers of a -thalassemia mutation, with about 
60,000 symptomatic individuals born each year ( Galanello & Origa, 2010 ).  
The clinical severity of β-thalassemia is determined by the amou nt of normal hemoglobin 
produced. It defines three  clinical and hematological conditions, classically referred to as  
-thalassemia minor, -thalassemia intermedia, and -thalassemia major. Patients with 
-thalassemia minor have mild or no anemia, and are usually asymptomatic carriers. Patients with 
-thalassemia intermedia have a moderately severe anemia , and may benefit from transfusions t o 
improve their quality-of-life, but later in life often develop a t ransfusion -dependent phenotype.  
Patients with -thalassemia major have a severe anemia and require frequent blood transf usions 
for life. Although there are many combinations of -globin mutations and gen etic disease 
modifiers associated with the transfusio n-dependent phenotype, collectively the condition is 
referred to in this study as transfusion -dependent β -thalassemia (TDT)  (Galanello & Origa, 2010 ). 
Improvements in health outcomes for patients with TDT have occurred over the  past 50 years as 
the benefits of a supportive care program were recognized . The program consists of regular RBC 
transfusions , starting as soon as the diagnosis is established and anemia develops . The RBC 
transfusions are accompanied by regular iron chelation therapy to reduce the ir on overload in vital 
organs caused by the transfusions.  The supportive care program significantly ameliorates the 
morbidity of TDT . However, the program is  time-consuming and resource -intense: treatment of a 
single patient  in 2011 for 50 years was estimated to cost $1,971,380 USD ( Koren et al., 2014 ) and 
result in 20% of treated patients having a life expectancy of less than 40 years (Modell et al., 2008 ). 
The only proven cure for TDT is allogeneic hematopoietic stem cell transplantation (HSCT).  
However, a llogeneic HSCT carries substantial risk of chronic morbidity (e.g., graft-versus-host 
disease [GVHD]) as well as a 10 -15% risk of death based on 5 -year mortality (Locatelli et al., 
2013; Baronciani et al., 2016 ). In addition, published reports show that  the probability of 
identifying a well -matched unrelated allogeneic donor within public registries is influenced by the 
ethnicity of the recipient; for example, among individuals of African descent, the probability of 
finding a suitable donor is estimated to be only 19% ( Gragert et al., 2014 ). Thus, many, if not 
most, recipients lack a human leukocyte antigen (HLA) -matched donor for allogeneic HSCT , 
making this potential curative treatment unavailable .  
In conclusion, the clinical paradigm for treatment of  TDT consists of life -long maintenance of a 
complex and often morbid  supportive care regimen to prolong survival and improve  quality-of-life, 
or, if available, allogeneic HSCT to cure TDT but with risk of chronic disease and life -threatening 
complications . These options underscore the urgent ne ed for new therapies for TDT. 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 20 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 1.2 Fetal Hemoglobin  
Fetal hemoglobin (HbF) is the major hemoglobin present during gestation until birth . HbF is 
generated by combining the protein product  of one of two β -like globin genes, G -globin and 
A-globin, known collectively as  -globin, with -globin protein as tetramers ( 22). HbF levels 
decline progressively  after birth as -globin protein production decreases , and around 6-12 months 
of age HbF is largely replaced by adult Hb, which consists of a tetramer of β-globin and -globin 
proteins (22). Concomitant with the  decline in HbF levels, the symptoms of TDT frequently 
become clinically apparent in infants . 
HbF normally only plays a minor role  in adult physiology . However , published studies have 
demonstrated that congenital, acquired, and drug -induced increases in HbF are associated with 
reduced morbidity and improved  clinical outcomes in patients with TDT.  For example, l arge 
unbiased genetic studies identified associations between TDT disea se severity and quantitative 
trait loci such as BCL11A, Xmn1HBG2 , and HBS1L-MYB that are associated with increased levels 
of HbF ( Thein et al., 2009 ), wherein t he level of HbF in many cases was observed to be  
proportional to the de gree of attenuation of TDT symptomology (Musallam et al., 2012 ). In 
addition, there are case reports of graft rejection after allogeneic HSCT for TDT in which elevated 
HbF levels persisted serendipitously after HSCT, and during which time the patients were 
transfusion -independent ( Ferster et al., 1995 ; Paciaroni & Lucarelli, 2012 ). 
1.3 BCL11A  in Hemoglobin Regulation  
BCL11A is a transcription factor that plays many roles in development and hematopoiesis. 
Genome-wide association and functional follow -up studies in cell and animal models have shown 
that BCL11A is an important silencer of HbF expression.  In a seminal study, dis ruption of BCL11A 
by erythroid -specific conditional knockout in a transgenic humanized mouse model of sickle cell 
disease (SCD) lead to  failure of hemoglobin switching , maintenance of  high-levels of HbF , and 
improvement s in hematologic and pathologic characteristics associated with SCD  (Xu et al., 2011 ). 
Inhibition of BCL11A therefore appears to  be a potentially effective strategy for treating  -globin 
disorders such as TDT and SCD in humans . However, targeting the BCL11A gene for therapeutic 
approaches poses challenges due to the crucial role of BCL11A in development and hematopoiesis  
(Brendel et al., 2016 ). An alternative strategy targets an enhancer element that is located in the 
upstream nonco ding region of the BCL11A locus. The enhancer  is required for BCL11A expression 
in erythroid cells but not in other lineages. The enh ancer was found to contain  a common genetic 
variation ass ociated with higher HbF levels (Bauer et al., 2013). It is therefore hypothesized that 
modification of this erythroid -specific enhancer of the  BCL11A gene could boost end ogenous HbF 
levels in erythroid  cells without deleterious effects on global BCL11A function (see Figure 1). 
 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 21 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021  
Figure 1: Regulation of hemoglobin switching by BCL11A 
Adapted from Hardison & Blobel 2013. 
 
1.4 Sangamo Zinc Finger Nucleases for Therapeutic Genome Editing  
Zinc finger nucleases ( ZFNs) are engineered proteins for site-specific genome e diting. They 
combine the DNA recognition specificity of zinc finger proteins ( ZFPs) with the nuclease domain  
of the type IIS restriction endonuclease  FokI to create double -strand breaks  (DSBs) at precise ly 
defined target sites in the genome. ZFPs contain arrays of Cys2 -His2 zinc fingers, each recognizing 
approximately 3 base  pairs of DNA. The FokI nuclease domain has no sequence specificity, and 
must dimerize to cut  DNA, which occurs efficiently only when 2 nuclease domain monomers are 
tethered next to each other in the proper  orientation along a strand of DNA . Consequently, DNA 
cleavage activity is achieved only by the simultaneous binding of 2 independent ZFNs to adjacent 
sequences in the correct spatial orientation.  Repair of the DSBs typically leads to the introduction 
of mutations, insertions, and deletions, termed “indels”, which can result in functional disruption 
of the target gene sequence.  
Sangamo has engineered a ZFN pair consisting of a 6 -finger ZFN (encoded by mRNA 
SB-mRENH1) and a 5-finger ZFN  (encoded by mRNA SB -mRENH2) that binds to a 33 base  pair 
(combined) target site in the erythroid-specific enhancer of the  human BCL11A gene (with 7 base 
pairs between the ZFP recognition sites) . Following the DSB created by the FokI nuclease domain 
of the ZFNs, indels are created in the enhancer with functional disruption of a binding site for the 
erythroid transcription factor GATA1 ( Vierstra et al., 2015 ; Canver et al., 2015 ) (see Figure 2). In 
a proof-of-concept study, targeted modification of the erythroid -specific enhancer of the BCL11A 
gene in hematopoiet ic stem/progenitor cells ( HSPCs) using ZFNs resulted in robust engraftment 
with high levels of HbF in an immunodeficient mouse model (Chang et al., 2017 ). 
Low fetal hemoglobin 
BCLllA Erythroid 
enhancer 
BCLllA 
protein 
HBGIHBGlJ HBB-5 
Repressed fetal 
''''J'"" 
Low expression 
of HbF Adult globin 
gene with 
mulion 
HbS 
t 
Sickle cell 
disease Elevated fetal hemoglobin 
Q LessBCUlA 
J 
Ameliorates 
disease symptoms High fetal hemoglobin 
~ 
No BClllA 
l 
"' Even more 
improvement 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 22 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021  
Figure 2: Gene Modification of BCL11A Erythroid Enhancer by Sangamo ZFNs  
 
1.5 Clinical Rationale for ST -400 Mechanism of Action  
Allogeneic HSCT for hereditary hematological conditions  bears a risk of graft failure and GVHD. 
Autologous HSCT has fewer of  these risks because the transplanted cells are derived  from the 
patient. As a result, autologous HSCT w ith a patient’s own genetically modified CD34+ HSPCs 
is expanding as a novel curative strategy.  
Recent clinical trials in patients with SCD and TDT using autologous CD34+ HSPCs  corrected ex 
vivo by a lentiviral vector with a functional -globin transgene demonstrated improvement in 
hematological parameters and decreased transfusion requirements ( Ribeil et al., 2017 ). Although 
promising, the use of a viral vector that randomly integrates in HSPC s after gene therapy is 
concerning as th ere is a theoretical risk of malignant transformation caused by random insertional 
mutagenesis and development of leukemia in a CD34+ HSPC sub -population ( Stein et al., 2010 ). 
ST-400 is a first-in-class ex vivo genome editing therapy  that is being developed for the treatment  
of TDT. ST-400 is composed  of autologous CD34+ HSPCs in which the erythroid -specific 
enhancer of the BCL11A gene is precisely modified without the use of integrating viral vectors 
(see Figure 3). The potential benefits of ST -400 include a) reduced risk of random insertional 
mutagenesis, and b) increased efficacy in TDT and SCD due to hemoglobin switching from 
defective Hb  to HbF com pared to approaches  that rely only on the over -expression of -globin. 
BCLllA 
Erythroid 
Enhancer right ZFN encoded by 
SB-mRENH2 
left ZFN encoded by 
SB-mRENH1 -J Double Strand Break (DSB) 
5'AGTGCAAGCTAACAGTTGCTTT TATCACAGGCTCCAGGAAGGG 3' 
3'TCACGTTCGATTGTCAACGAAAATAG TGTCCGAGGTCCTTCCC 5' 
Non-homologous -J end joining (NHEJ) 
5'AGTGCAAGCTAACAGTTGCTTTTATCACAGGCTCCAGGAAGGG 3' 
3'TCACGTTCGATTGTCAACGAAAATAGTGTCCGAGGTCCTTCCC 5' Wild type 
5 1 AGTGCAAGCTAACAGTTGCTTTTATC TATCACAGGCTCCAGGAAGGG 3' Insertion 
3'TCACGTTCGATTGTCAACGAAAATAG ATAGTGTCCGAGGTCCTTCCC 5' 
= "indels" 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 23 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021  
 
Figure 3: ST-400 Treatment  
 
1.6 Preclinical Pharmacology Studie s 
Nonclinical studies were performed to support the us e of ZFN mRNAs SB -mRENH1 and 
SB-mRENH2 in clinical studies. The studies characterized CD34+ HSPCs derived from healthy 
subjects and transfected with ZFN mRNAs SB-mRENH1 and SB -mRENH2 with regard to:  
a) Level of disruption of the erythroid -specific enhancer of the BCL11A gene. 
b) Potential of the transfected CD34+ HSPCs to differentiate into erythroid progeny (including 
assessment of cellular levels of γ -globin mRNA and protein in the erythroid progeny of the 
CD34+ HSPCs) in vitro. 
c) Comparative activity and specificity of the original ZFN pair (S T-mRENH) and the optimized 
ST-400 ZFN pair (ST -mRENH1 and ST -mRENH2) in K562 cells and CD34+ HSPCs in vitro. 
d) Potential of the transfected CD34+ HSPCs  to engraft in NSG mice and differentiate into  
various hematopoietic lineages . 
1.6.1 In Vitro Studies 
For all of these studies, mobilized human CD34+ HSPCs were collected by apheresis from healthy 
subjects and purified. Purified CD34+ HSPCs were transfected with ZFN mRNAs SB-mRENH1 
and SB-mRENH2 . Untransfected  CD34+ HSPCs from the same sub jects served as controls. 
Forty-eight hours after transfection, the CD34+ HSPCs were harvested and frozen for use in three 
in vitro studies to determine erythroid differentiation potential of the transfected CD34+ HSPCs 
and to quantify on -target and off -target loci modification by the optimized ST-400 ZFN pair. 
 
\s 
j 
6 1' ! ··· ....... l. ······················ . 
••••••• ♦ 
\ 
I , 
~ ) 
I 
Patient with TOT _sr_-_40_0_1N_F_u_s_1o_N~ l~ ENGRAFTMENT 
\ I ( 
I~ 
blood stem cell ST-400 stem cell ) t Fetal 
hemoglobin 
I Transfusion T dependence 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 24 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 1.6.1.1  In Vitro Erythropoiesis  
To analyze the effects of ZFN -mediated gene editing of the  human erythroid -specific enhancer of 
the BCL11A gene, the transfected  CD34+ HSPCs wer e placed in an in vitro erythropoiesis model 
known as “cRBC pooled differentiation” ( Giarratana et al., 2011 ). Disruption  of the 
erythroid-specific enhancer of the BCL11A gene was measured by MiSeq  deep sequencing, and 
found to be  ~75% indels, which is within the range expected during production of clinical material.  
Reversed-phase UPLC of protein samples demonstrated that the ratio of γ -globin to β-globin and 
γ-globin to α-globin was increased app roximately 3 to 4-fold in the erythroid progeny of the 
transfected CD34+ HSPCs compared to the untransfected CD34+ HSPCs. Thus, targeted gene 
modification by the optimized ST -400 ZFN pair resulted in a clinically-relevant effect , i.e., 
elevation of γ-globin protein. Additional details are provided in the Investigator’s Brochure.  
1.6.1.2  Colony-forming Unit (CFU) Potential  
For assessment of the functional potential of human CD34+ HSPCs transfected with ZFN mRNAs 
SB-mRENH1 and SB -RENH2, t he number and morphology of c olonies formed by a fixed number 
of input cells in the CFU assay was used. The results showed that transfected CD34+ HSPCs  
differentiate d into all hematopoietic lineages , including erythroid progenitors  (CFU-E and 
BFU-E), granulocyte/macrophage progenitors  (CFU-G/M/GM) , and multi -potential progenitors  
(CFU-GEMM), without significant effects on differentiation potential compared to controls . 
Additional details are provided in the Investigator’s Brochure.  
1.6.1.3  Comparison of the Original and Optimized ZFN Pairs 
Clinical development for the ST-400 β-thalassemia program yielded two related ZFN pairs, an 
original pair and a final optimized ST-400 ZFN pair that is much more precise. The comparative 
functional precision of cleavage of the original and optimized ST-400 ZFN pairs was evaluated . 
Candidate off -target sites were identified using an unbiased oligonucleotide duplex integration 
methodology, followed by analysis of off-target cleavage via MiSeq deep sequencing analysis . 
The results showed that  the optimiz ed ST-400 ZFN pair had a high level of both activity and 
specificity (>80% on -target modification  in CD34+ HSPCs, and 0.15% aggregate off -target 
indels), with a more than 260-fold improvement compared to the original ZFN pair. Additional 
details are provid ed in the Investigator’s Brochure.  
1.6.2 In Vivo Studies 
Human CD34+ HSPCs transfected with ZFN mRNAs SB-mRENH1 and SB -mRENH2  were 
assessed in vivo for their ability to engraft  in NOD/SCID/IL2rγnull (NSG) mice, maintain the 
disruption of the erythroid -specific enhancer of the BCL11A gene, and after engraftment in  NSG 
mice differentiate into erythrocytes in vitro. 
Female NSG mice were engrafted with 1 x 106 SB-mRENH1 -/SB-mRENH2 -transfected CD34+ 
HSPCs (from two healthy donors) or untransfected CD34+ HSPCs . Mice were followed for up to 
19 weeks prior to scheduled necropsy.  
All animals survived to their scheduled termination. The levels of modification at the 
erythroid-specific enhancer of the BCL11A gene were 79% and 75% in donors PB -MR-003 and 
PB-MR-004, respectively, at input after transfection, and dropped to stable levels of 42% and 50%, 
respectively, in peripheral blood cells at Week 19. Peripheral blood samples had almost identical 
modification levels as the corresponding bone marrow samples, and c omparable modification was 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 25 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 observed in both BCL11A -dependent ( CD19+ B cells; CD34+CD38high primitive progenitors) 
and BCL11A independent (CD33+ myeloid cells) lineages. Overall, there was no difference 
between ZFN -treated and untreated CD34+ HSPCs in engraftment of the hematopoietic lineages.  
Bone marrow was collected from the treated mice to assess for in vitro erythroid differentiation. 
The ratios of γ-globin to β-globin mRNA and γ-globin to α-globin mRNA were increased 1.5 to 
3-fold, respectively, at Week 19. UPLC analysis to determine the ratios of γ -globin to α-globin 
protein and −globin to β -like globin protein showed similar increases.  
To summarize, these studies demonstrated that CD34+ HSPCs tran sfected with the ST -400 
optimized ZFN pair had a similar engraftment and differentiation potential as control untransfected 
CD34+ HSPCs. The transfected CD34+ HSPCs were durably maintained in the peripheral blood, 
the bone marrow, and in all lineages studi ed, with gene modification levels of 42% and 50% 
detectable at Week 19 . Additional details are provided in the Investigator’s Brochure . 
1.7 Clinical Studies 
This is a first-in human study for ST-400.  
Several human clinical trials using ex vivo ZFN delivery for gene modification are ongoing or have 
been completed by the Sponsor ( Tebas et al., 2014 ). These trials evaluated SB-728-T, an 
autologous enriched CD4+ T -cell product tran sfected ex vivo with ZFNs  that target the CCR5 
gene, in >80 HIV-infected subjects at doses ranging from 5 to 36 x 109 cells. The longest duration 
of follow -up has been over 5 years in the first subject infused. SB -728-T infusions were well 
tolerated with mostly mild and moderate reversible infusion related AEs (see Section 1.9.1.1 for 
additional details ). 
1.8 Targeted Patient Population  
The targeted patient population of this study will be adult patients with TDT who require 8 or more 
RBC transfusion  events per year and who are medically approp riate for the apheresis, mobilization, 
and conditioning regimen .  Patients with various genotypes leading to severe beta thalassemia 
syndrome, therefore, will be considered for this study so long as they meet the clinical definition 
of TDT.  Patients with sickling disorders, including Hemoglobin S/Beta -thalassemia, wil l not be 
considered for this study.  
1.9 Risk Benefit Assessment  
The risk-benefit of ST-400 treatment in patients with TDT is currently unknown . 
1.9.1 Assessment of Risk  
This is the first study in which ST-400 has been administered to humans, but the expectation of a  
favorable risk profile is supported by results obtained with previous studies in humans conducted 
using ZFNs in an autologous enriched T -cell product . Moreover , several in vitro and in vivo studies 
were conducted to assess the safety of ST -400.  
Serious allergic reaction in association with ST -400 administration has been reported in one 
subject, characterized by symptoms of dysgeusia, cold sensation, chest pressure, dyspnea, 
hypotension, and bradycardia. The event was assessed as grade 3 an d resolved within two hours 
of onset after treatment with IV fluids, diphenhydramine, hydrocortisone, and ranitidine. The 
reaction was assessed as likely related to the DMSO in the investigational product.  
 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 26 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 1.9.1.1  Previous Experience with ZFNs in Humans  
SB-728-T, an autologous T-cell product consisting of CD4+ cells modified by ZFNs at the CCR5 
gene locus , was administered  to more than 80 human immunodeficiency virus (HIV)-infected 
subjects in 4 clinical trials . SB-728-T infusions were well tolerated with mostly mild and moderate 
reversible infusion -related AEs. One subject experienced a serious infusion related reaction with 
symptoms of fever, chills, joint pain, and back pain one day after SB -728-T infusion, which was 
assessed as related to the study treatment. There have been no reports of malignancy in these 
studies to date.  
1.9.1.2  In Vitro Studies 
The in vitro studies conducted included analysis of CD34+ HSPC s derived from healthy subjects 
and transfected with ZFN mRNAs SB-mRENH1 and SB -mRENH2 with regard to presence and 
type of mutations at the erythroid-specific enhancer of the BCL11A gene, karyotype, induced DSBs  
in DNA, molecular translocation, and evaluation of potential off-target transcriptional activity .  An 
in vitro tumorigenesis study evaluated ZFN mRNAs SB-mRENH1 and SB-mRENH2 in a human 
fibroblast cell line.  
Off-Target Genome Modifications by ST-400 ZFNs  
The optimized ST-400 ZFN pair is highly specific for the erythroid -specific enhancer of the 
BCL11A gene and has but a minimal amount of detectable off -target activity. To further 
characterize candidate off -target loci and cleavage targets, indel analyses were conducted using 
MiSeq deep DNA sequencing and NextSeq ultra -deep DNA sequencing. MiSeq analysis showed 
very low levels of  off-target cleavage  of 0.15% or less. NextSeq analysis revealed extremely low 
levels of off -target cleavage of less than 0.01%. In comparison, i ndel levels at the targeted 
erythroid-specific enhancer of the BCL11A gene ranged from about 79 to 86%.  These genome 
wide analyses indicate that indel levels at the BCL11A on -target locus exceed the levels of 
modification at all identified off -target site s combined by more than a factor of 300.    
To determine the significance of the minimal off -target activity, a bioinformatics approach was 
employed in conjunction with a literature review of identified loci. For all identified off -target 
events, there was  no evidence of modifications to coding regions of genes involved in critical 
hematopoietic functions. In addition, off -target events did not lead to modifications that are known 
to be associated with hematopoietic malignancies in humans. Additional detail s are provided in 
the Investigator’s Brochure . 
Karyotyping of ST -400 HSPCs  
Karyotype analysis was performed to evaluate for potential abnormal chromosomal morphologies 
by the optimized ST -400 ZFN pair in CD34+ HSPCs derived from healthy subjects. The  analysis 
showed that all cells were of human origin, and none had gross chromosomal abnormalities . These 
results demonstrated that there were no gross structural or numerical chromosomal abnormalities 
in CD34+ HSPCs transfected with the optimized ST -400 ZFN pair. Additional details are provided 
in the Investigator’s Brochure . 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 27 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 Double Strand Breaks (DSBs) by ST-400 ZFN Pair  
To characterize the profile of DSBs created by the optimized ST -400 ZFN pair, a p53 -binding 
protein 1 ( 53BP1) assay was used. In this assay, the 53BP1 is recru ited to sites of DSBs within 
24 hours after they occur and used to visualize the DSBs by immunofluorescence microscopy 
(Schultz et al., 2000 ). The 53BP1 staining resulted in distinct bright foci marking t he locations of 
DSBs. The results of this study  demonstrated that t he induction of 53BP1+ foci was transient, 
returning to background levels by 5 days post -transfection . Samples collected in parallel for MiSeq 
analysis showed that gene modification at the erythroid-specific enhancer of the BCL11A gene was 
~79% indels at 2 d ays post-transfection . Thus, gene modification levels remained high as 53BP1 
immunostaining levels decreased, demonstrating that the drop in 53BP1 signal was not due to loss 
of transfected cells over time. These findings  are consistent with a transient (about 48 hour) period 
of ZFN expression and activity after transfection  and rapid repair of the DSB . Additional details 
are provided in the Investigator’s Brochure . 
Colony Formati on in Soft Agar by ST -400-Transfected Fibroblasts  
For assessment of transformation/t umorigenic potential, anchorage -independent growth of human 
WI-38 fibroblasts  transfected with ZFN mRNAs SB -mRENH1 - and SB-mRENH2 was assessed 
in a soft agar transformation  assay (Shin et al., 1975 ). Gene modification levels were measured at 
~73% indels in the genetically modified WI -38 cells compared  to ~0.3% in untransfected 
WI-38 cells. No anchorage -independent growth of the transfected and untrans fected WI -38 cells 
was observed at any time point. The results show t hat transfection  with ZFN mRNAs 
SB-mRENH1 and SB -mRENH2 , and the resultant ZFN-mediated disruption at the 
erythroid-specific enhancer of the BCL11A gene in WI-38 cells, do not promote tumorigenicity.  
Additional details are provided in the Investigator’s Brochure . 
Molecular Translocation by ST-400 ZFN Pair  
In depth characterization of rare translocation events occurring between the on -target locus 
(erythroid -specific enhance r of the BCL11A gene) and all known sites of off -target cleavage was 
conducted using a TaqMan -based assay developed by Sangamo that provides highly sensitive 
detection of translocation events at frequencies approaching one in 105 queried genomes. The 
assay was used to query for the presence and level of reciprocal translocations between the 
intended cleavage target in the erythroid -specific enhancer of the BCL11A gene and each 
previously identified off -target site. The assay revealed very low translocation levels involving 
just two of the off -target sites, with translocation frequencies ranging from 1 in 105 to 2 in 
107 genomes. To determine the significance of these rare translocations, a bioinformatics approach 
was employed in conjunction with a literature  review. None of the identified translocation events 
were known to be associated with hematopoietic malignancies in humans. Additional details are 
provided in the Investigator’s Brochure . 
Off-target Transcriptional Effects by the ST -400 ZFN Pair in Erythroid Progeny  
To assess off -target transcriptional activity of the optimized ST -400 ZFN pair, the expression 
profile of 11 genes flanking the BCLA11A  gene were analyzed using MiSeq deep sequencing. 
RNA was collected from the transfected  CD34+ HSPCs on Day 14, at which t ime gene 
modification levels at the erythroid -specific enhancer of BCL11A gene were quantitated  as >50% 
compared to controls. Levels of γ-globin mRNA in the transfected CD34+ HSPCs were increased 
about 2-fold (normalized to 18s RNA), reflecting decreased B CL11A expression resulting from 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 28 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 the on-target elimination of the GATA1 binding site in the erythroid -specific enhancer of the 
BCL11A gene. In contrast, the expression levels of the 11 genes flanking the BCL11A gene were 
similar to those of the 11 genes in the control cells. Expression levels of 4 other genes regulated 
by GATA1 ( KLF1, SCL4A1, ZFPM1 and ALAS2) also were not affected. These results show that 
the activity of ZFN mRNAs SB-mRENH1 and SB -mRENH2  is restricted to repression of BCL11A 
gene transcript ion and its consequent downstream effects. Additional details are provided in the 
Investigator’s Brochure . 
1.9.1.3  In Vivo Studies 
A previously conducted in vivo animal study found that a knockout of the mouse erythroid -specific 
enhancer of the BCL11A gene has no significant effects on erythropoie sis other than elevation of 
γ-globin levels  (Smith et al., 2016 ). 
To evaluate the potential tumorigenicity of ZFN -transfected HSPCs , an in vivo animal study was 
conducted in immune -deficient NSG mice . NSG mice are considered an optimal model for such 
studies because they accept transplantations of human HSPCs and establish long -lived grafts of 
the HSPCs and their progeny ( Christianson et al., 1997 ; Shultz et al., 2005 ). The mice were 
engrafted with human CD34+ HSPCs derived from healthy subjects and transfected with  ZFN 
mRNA SB-mRENH. SB -mRENH encodes  the original two BCL11A enhancer-specific ZFNs, 
which are known to result in qualitatively equivalent gene modification at the erythroid-specific 
enhancer of the BCL11A gene as the optimized ZFN mRNAs SB-mRENH1 and SB -mRENH2 . A 
total of 325 pre -conditioned female NSG mice were engrafted with 1 x 106 SB-mRENH-
transfected HSPCs (n = 225) or untransfected HSPCs (negative control; n = 100), and maintained 
for up to 20 weeks prior to a scheduled necropsy. The engrafted m ice were observed daily for 
evidence of AEs, underwent detailed clinical observation twice weekly, and were weighed weekly .  
The cell dose of 1 .0 x 106 CD34+ HSPC per mouse is approximately 5 .0 x 107 cells/kg (assuming 
a 20 g mouse), which is 5 -fold higher than the target clinical dose (1.0  x 107 cells/kg) for patients.  
As 225 mice received 1.0 x 106 ZFN-treated cells, a total of 2.25 x 108 cells were evaluated in the 
tumorigenicity study.  
MiSeq deep sequencing confirmed that gene modification levels at the erythroid -specific enhancer 
of the BCL11A gene of 43% or greater throug hout the study until completion of the experiment at 
Week 20. FACS analysis and multi -lineage differentiation of HSPCs showed successful 
engraftment, with hematopoietic progeny measured in blood and bone marrow of all animals 
during this study. Survival to  study termination was ~95% (307/325), with 18/325 unscheduled 
deaths. Nine of the 18 early deaths were pr ocedure- or husbandry -related. The remaining 9 deaths 
(2 in the untransfected control group, 7 in the ZFN -transfected group) were mice euthanized in 
poor clinical condition, mostly related to bone marrow hypoplasia caused by the irradiation 
procedure used for transplan tation of human HSPCs.  
In surviving animals, there were no significant differences in mean body weights o r body weight 
gain between anim als that received transfected or untransfected HSPCs over the course of the 
study.  There were no treatment -related effects on peripheral blood and bone marrow morphology  
or lymphocyte counts.  There were no pathologic findings related to administration of BCL11A 
enhancer-modified CD34+ HSPC or neoplasms shown to be of human origin.  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 29 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 In summary, this in vivo tumorigenicity study in engrafted NSG m ice demonstrated no evidence 
of toxicity or neopla sia attributable to transfection with ZFN mRNA SBmRENH. Additional 
details are provided in the Investigator’s Brochure . 
1.9.2 Assessment of Benefit 
TDT is associated with significant morbidity and mortality.  
Over the past several decades, the incidence of early  mortality due to TDT has been reduced  with 
current supportive therapy, which consists of frequent and lifelong RBC transfusions and daily 
iron chelation therapy. However, th is treatment is burdensome and expensive . Moreover, RBC 
transfusions cause iron overload that can be fatal when adherence to iron chelation therapy  is poor.  
β-thalassemia can be cured currently only by allogeneic HSCT. However, allogen eic HSCT is 
performed  infrequently world-wide due to limited donor availability, toxicity , and cost. 
Furthermore, allogeneic HSCT bears risks of death and long-term complications (e.g., GVHD). 
Thus, due to the limitations of existing therapies for TDT, there is an unmet medical need for 
which ST-400 could potentially provide life -long clinical benefit. 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 30 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 2. STUDY OBJECTIVES  
It is hypothesize d that treatment with ST-400 will induce a sustained high-level expression of 
-globin and production of HbF  in patients with TDT , and ultimately reduce or eliminate the need 
for regular life -long RBC transfusions .  
2.1 Primary Objective  
The primary objective of this study is to evaluate the safety and tolerability of ST -400 in patients 
with TDT. 
2.2 Secondary Objective  
The secondary objective of this study is to assess the efficacy of ST-400 in patients with TDT. 
2.3 Exploratory Objectives  
The exploratory objectives  of this study are  to: 
• Evaluate the gene modification characteristics (% and durability) at the erythroid -specific 
enhancer of the BCL11A gene after ST -400 treatment.  
• Assess the impact of ST-400 on the b iochemical, imaging, functional, and bone marrow 
evaluations related  to β-thalassemia and HSCT.  
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 31 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 3. STUDY OUTCOME MEASURES  
3.1 Primary Outcome Measure s 
Safety and tolerability will be assessed by incidence of adverse events (AEs) and serious AEs 
(SAEs). Additional safety evaluations will include:  
• Routine hematology and chemistry laboratory testing, vital signs, physical exam, 
electrocardiogram ( ECG), echocardiogram (ECHO), pulmonary function tests (PFTs), 
bone marrow aspiration, and concomitant medications.  
• Kinetics and success of hematopoietic reconstitution.  
• Duration of hospitalization after conditioning . 
• Screening for potential development of hematological malignanc ies. 
3.2 Secondary Outcome Measure s 
Change from baseline will be assessed  by: 
• Clinical laboratory measurement of Hb fractions (A and F in g/dL) and percent HbF . 
• Calculation of annualized frequency and volume of packed red blood cell (PRBC) 
transfusions after ST -400 infusion as compared to baseline transfusion support in the 
2 years prior to screening.   
3.3 Exploratory  Outcome Measure s 
To assess the following:  
• Percentage  and durability of gene modification at the erythroid -specific enhancer (ESE) 
of the BCL11A genes. 
• Change from baseline in  
o thalassemia -related disease biomarkers . 
o endocrine function by lab testing.  
o cardiac function by  ECHO. 
o iron content by MRI (liver and heart) . 
o bone mineral density by dual-energy X-ray absorptiometry ( DXA). 
o quality-of-life by Short Form Health Status Survey ( SF-36 Survey). 
o overall function by Karnofsky performance score . 
o Percentage of F -cells. 
• Efficiency of apheresis procedure.  
• Difference between % indels in ST -400 product and indels detected in bone marrow and 
blood following ST -400 infusion.  
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 32 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 4. STUDY DESIGN 
4.1 Overview 
This is a Phase 1 /2, open-label, multi-center, single-arm study.  
A total of five (5) to s ix (6) subjects with a diagnosis of TDT will be enrolled and treated.  
Eligible subjects will be enrolled and undergo apheresis to collect autologous CD34+ HSPCs. The 
CD34+ HSPCs will be treated ex vivo by transfection with ZFN mRNAs SB -mRENH1 and 
SB-mRENH2 to manufacture the study drug , ST-400. ST-400 will be cryopreserved u ntil the 
subject is ready for conditioning . 
Subjects will receive conditioning  therapy with IV busulfan  before being infused with ST -400. 
Clinical and laboratory data wi ll be collected for a total of 15 6 weeks post-infusion of ST -400. 
4.2 Justification of Stud y Design 
The primary objective of this first -in-human study is to assess th e safety and tolerability of ST -400. 
Due to the invasive nature of the apheresis procedure and the potential toxicity of IV busulfan , no 
treatment control group is included in this study. A minimum of 2 years of retrospective clinical 
and hematological data will be collected for each subject, thus each subject will serve as their own 
control to provide reference data for evaluation of change from baseline of the study assessments , 
including transfusion require ments and circulating Hb and HbF levels .  
4.3 Number of Subjects  
Six (6) subjects who satis fy all eligibility criteria will be enrolled and treated in this study. Enrolled 
subjects who do not receive ST -400 or who are lost to follow -up or withdraw from the stu dy before  
the Week 26 visit in the Primary Study Period (beginning with ST -400 infusion) will be replaced.  
The first 3 subjects will be considered  sentinel subjects, and the second and third sentinel subjects 
will not begin conditioning with IV busulfan  until the subject previously enrolled has achieved 
successful hematopoietic reconstitution . 
4.4 Dose and Dose Justification  
The minimum  cell dose of ST -400 is 3.0 x 106 cells/kg, administered IV no sooner than 72 hours 
after the final dose of IV busulfan  in the conditioning  phase. To reduce the risk of graft failure, the 
minimal dose of ST -400 required in this study exceeds the generally recommended minimum cell 
dose of 2.0 x 106 CD34+ HSPCs /kg for autologous HSCT (Duong et al., 2014 ). To achieve the 
highest likelihood of efficacious ST -400 engraftment, the  target dose of ST -400 is 
10 x 106 cells/kg, and the maximum dose that may be given is 20 x 106 cells/kg. 
To put the human cell dose in perspective to the number of t reated cells evaluated in the 5 -month 
NSG mouse tumorigenicity study, t he mouse cell dose of 1 .0 x 106 CD34+ HSPC  is approximately 
5.0 x 107 cells/kg, which is 5 -fold higher than the target clinical dose (1.0  x 107 cells/kg) for 
patients.  As 225 mice received 1.0 x 106 ZFN-treated cells, a total of 2.25 x 108 cells were 
evaluated in the tumorigenicity study.  There was no evidence of treatment -related toxicity or 
neoplasia in the 5 -month mouse study.   
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 33 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 4.5 Study Duration 
The duration of study part icipation will be up to 18 2 weeks for each subject , divided into  4 study 
segments: 
• Screening  (up to 6 weeks)  
• Mobilization , Apheresis, Conditioning  (up to 20 weeks) 
• Primary Study P eriod (starting with ST-400 infusion on Day 0; 52 weeks) 
• Follow-up Study Period (104 weeks)  
To assess long -term safety, subjects will be asked to participate in a separate long -term follow -up 
(LTFU) study after they complete this study. The  total combined (current and LTFU studies) 
follow up period will last 15 years.  
4.6 Visit Schedule  
Subjects will complete all screening visit procedures and will have eligibility confirmed before 
proceeding t o mobilization & apheresis (see Figure 4). Subjects will be hospitalized at the study 
center following IV busulfan conditioning and ST -400 infusion. In line with typical clinical 
practice, subjects may be discharged following primary hospitalization upon achieving 
(1) neutrophil recovery (defined per protocol as ANC ≥ 500 cells/µL on 3 consecutive days) and 
(2) all other institutional criteria required for discharge following standard  myeloablative 
autologous H SCT (estimated 2 to 4 weeks; however, duration is variable depe nding on each 
subject’s clinical course) .  Subjects will be evaluated at the study center weekly until Day 42, then 
at Days 56 and 90, and then every 13 weeks until the final Week 156  visit. Each subject will thus 
have a total of 3 years of monitoring following ST -400 infusion . For a detailed schedule of visits 
and procedures see Section 7 and Appendix 1. 
 
Figure 4: Schema of Study Visits  
 
4.7 Study Procedures  
Subjects who meet eligibility criteria and are enrolled will be scheduled for the Mobilization & 
Apheresis visit to prepare for  and subsequently begin mobilization . Subsequently, CD34+ HSPCs 
will be mobilized in  each subject following G-CSF administration on Days 1 -6 of mobilization  
(plus Day 7 if rescue treatment is collected on Day 7 ) and plerixafor  administration  prior to each 
apheresis (Days 5 and 6, plus Day 7 if rescue treatment is collected on Day 7) . Timing of plerixafor 
♦ 
screening ♦ 
mob.& 
apher. 
( Subject participation : 182 weeks ♦ 
baseline 
(d-20 to d-7) ♦ ♦ ♦ ♦ 
busulfan ' DO D1-D42 Wk 26-52 
ST-400 (weekly) (every 13 weeks) 
infusion D56, D90 
Hospital or 
Acute Care Facility 
'Administered daily for 4 days, or every 6 hours for4 days. Final dose administered no less than 72 hours prior to infusion on Day 0. ♦ 
Wk 52-156 
( every 13 weeks) 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 34 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 administration with respect to the start of apheresis may be approximately 10 to 12 hours before 
apheresis, but is at the discretion of the Investigator.  T iming of G-CSF administration may be 
1-2 hours prior to the start of apheresis, but is at the discretion of the Investigator  (see Figure 5). 
Mobilized CD34+ HSPCs  will be collected from each subject by apheresis o n Days 5 and 
6 (+ Day 7 if needed to secure the rescue treatment)  with a target of 25 x 106 CD34+ HSPCs/kg  
total to be submitted for manufacturing , although smaller yields are acceptable. Within this 
timeframe, apheresis and mobilization may be started earlier and/or discontinued earlier based on 
institutional practices, cell yields, and Investigator ’s judgement. Splenectomized subje cts will 
receive a reduced dose  of G-CSF, with further dose adjustment as necessary, to target a WBC 
below 100,000 cells/ L. G-CSF and plerixafor dosing, timing, or route of administration may be 
modified or discontinued at the discretion of the Investigator  if the WBC exceeds 100,000 cells/ L 
or if the subject becomes symptomatic .  
  
 
Figure 5: Schema of  Mobilization and Apheresis  
 
The collected cells of each subject will be split into 2 portions, one portion for ST -400 drug 
manufacturing and the other portion set aside in the event a rescue treatment  is indicated .  
The rescue treatment portion  must compr ise a minimum of 2.5 x 106 CD34+ HSPCs/kg.  The rescue 
treatment portion  will be cryopreserved unmodified and stored at the study site for availability in 
the event of delayed hematopoietic reconstitution or graft failure with aplasia. If the first apheresis 
cycle does not mobilize the minimum number of  CD34+ HSPCs required for ST -400 drug 
manufacturing and for rescue treatment, the mobilizat ion procedure may be repeated. Selection of 
the timing of a second apheresis will be at the discretion of the Investigator  based on the subject’s 
clinical status, but may occur no sooner than 2 weeks after the  initial apheresis . 
t Day 1 Day 2 Day 3 
t t 
t Daily dose of G-CSF 
t Daily dose of plerixafor * Apheresis Day 4 Day 5 Day 6 
t* t Day 7 
* Conditional : for obtaining required cells for rescue treatment if not previously secured 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 35 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 Mobilized and harvested  cells collected for ST-400 manufacturing will be sent by courier to the 
Good Manufacturing Practices ( GMP) manufacturing facility . A CD34+ cell selection followed 
by transfection  with ZFN mRNAs SB-mRENH1 and SB-mRENH2  to disrupt the erythroi-specific 
enhancer of the BCL11A gene will be performed to generate  the ST-400 study drug. ST-400 will 
be cryopreserved and stored until all the clinical protocol segments up to and including the 
Baseline visit procedures are completed and the subject is ready for ST-400 infusion . 
A subject will not proceed to conditioning  with IV busulfan  until a sufficie nt quantity of rescue 
treatment is obtained and ST-400 is manufactured, passes quality control and release testing, and 
is confirmed as receiv ed at the clinical site . 
After receipt of ST-400 at the clinical site , subjects will be admitted to the hospital to begin IV 
busulfan in a dedicated transplant unit . Subjects will receive a myeloablative regimen of busulfan  
(3.2 mg/kg/day ; administered IV via central venous catheter  either once daily or every 6 hours ) for 
4 days (total dose of 12.8 mg/kg , which is considered standard -of-care for autologous 
transplantation ). After the first dose, t he IV busulfan  dose will be adjusted based on 
pharmacokineti c sampling and study center practices  to target an area under the curve  (AUC) of 
4,000-5,000 µmol*min for daily dosing or an AUC of 1, 000-1,250 µmol*min for every 6  hour 
dosing for a total regimen target AUC of 16,000 -20,000 µmol*min.  
IV busulfan  pharmacokinetic targeting may be modified for subsequent subjects based on 
experience with previous subjects after discussion with the Safety Monitoring Committee ( SMC). 
Therapeutic drug monitoring  to determine clearance  of busulfan after 4 days of dosing is complete  
is not required but may be performed at the discretion of the Investigator  in accordance with study 
center practices.  
No sooner than 72 h ours after the final dose of IV busulfan  in the conditioning  phase, subjects will 
be infused on Day 0 with  ST-400. The minimum cell dose of ST-400 to be administered is 
3.0 x 106 cells/kg. Subjects may receive more than one lot of ST -400 if multiple apheresis cycles 
were performed  to achieve the minimum cell dose. 
The first 3 subjects will be considered sentinel subjects and will be enrolled sequentially as follows 
(see Figure 6): The first subject will be enrolled and rece ive ST-400 infusion. T he second subject 
may proceed with  CD34+ HSPC mobilization  and drug manufacturing at any time but shall not 
proceed to conditioning  or ST-400 administration until the first subject has  achieved successful 
hematopoietic reconstitution  as defined by absolute neutrophil count ( ANC) ≥500 cells/µL for 
3 consecutive days  and platelet count ≥20,000 cells/µL for 3 consecutive measurements  spanning 
a minimum of 3 calendar days (in the absence of platelet transfusion in the preceding 7 days). 
Similarly, the third subject shall not proceed to conditioning  or ST-400 administration until the 
second subject has  achieved successful hematopoietic reconstitution .  
If unexpected toxicities  are reported, enrollment and dosing will be paused pendi ng SMC review. 
The SMC will also provide recommendations on any ST-400-related AEs that should be 
characterized as dose -limiting toxicities of ST -400 treatment .  
After the 3 sentinel  subjects have achieved successful hematopoietic reconstitution , all safety data 
from the s tudy will be reviewed by the SMC. If no study suspension or stopping rules are met and 
no significant safety concerns related to ST -400 are reported, the subsequent 3 subjects may 
receive ST -400 concurrently without waiting for other subje cts to engraft. 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 36 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 Should a subject experience  delayed hematopoietic reconstitution or graft failure with aplasia, the 
subject will receive the rescue treatment consisting of  unmodified , autologous CD34+ HSPCs , and 
a SMC safety review will be performed . Delayed hematopoietic reconstitution or g raft failure with 
aplasia is defined as persistent ANC <500 cells/µL through Day 42 post -infusion. The rescue 
treatment may be administered  at any time  after ST-400 infusion if needed at the discretion of the 
Investigator  based on clinical indications for patient safety . 
 
Figure 6: Schema of Subject Enrollment  
 
4.8 Study Suspension Rules  
Study enrollment and dosing  will be suspended pending SM C evaluation of clinical trial safety 
data if any of the following occurs :  
1. A subject develops a Gr ade 3 or higher AE assessed as related to ST-400 by the Investigator  
or Sponsor  
2. A subject experiences  delayed hematopoietic reconstitution  or graft failure wi th aplasia 
requiring rescue treatment.  
3. A subject develops a malignancy  (excluding non -melanoma skin cancer and cervical 
cancer in situ) . 
4. A subject dies.  
5. The SMC and/or Sponsor determine that an event or current data warrant further evaluation 
by the SMC.  
♦ 
screening ♦ ♦ 3 screening 
J' ~ 11 ~ ♦ ♦ ♦ 
baseline busu"an DO 
♦ 
screening ~ 
►11-+ ♦ ♦ ♦ 
baseline busu/fan DO 
♦ ♦ ♦ ♦ 
_l(flf26-52 
screening ~11 .. baseline busuffan DO ♦ 
~26-52 ♦ 
fil65-156 
♦ ♦ ♦ 
baseline b,usulfan DO ♦ 
Wk 26-52 ♦ 
Wk 65-156 
r Successful hematopoietic reconstitution ♦ 
~65-156 ♦ 
Wk 65-156 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 37 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 Upon suspension, the SM C will be convened and will evaluate all data and provide 
recommendations on  whether enrollment or dosing  should continue, whether changes should be 
made to the study , and, in consultation with Sponsor, whether the study should be sto pped. 
Subjects who have already been dosed with ST -400 will continue to be followed for safety 
monitoring as part of the clinical trial.   
4.9 Study Stopping Rules  
Study enrollment and dosing will be permanently discontinued if  any of the following occurs : 
1. Sponsor, in consultation with the SM C or Regulatory Agency,  decides for any reason that 
subject safety may be compromised by continuing the study . 
2. A subject develops a malignanc y assessed as related to ST -400. 
3. Any other risk o f ST-400 deemed medically unacceptable by the Sponsor  is identified . 
4. Sponsor decides to discontinue t he development of ST -400. 
Subjects who have already been dosed with ST -400 will continue to be followed for safety 
monitoring as part of the clinical trial . 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 38 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 5. SUBJECT SELECTION  
5.1 Inclusion Criteria  
1. Signed informed consent form ( ICF). 
2. Male or female between 18 and 40 years of age, inclusive . 
3. Clinical diagnosis of TDT with >8 documented RBC transfusion  events per year on an 
annualized basis in the 2 -years prior to Screening. 
4. Confirmed −thalassemia diagnosis by molecular genetic testing. 
5. Clinically stable and eligible to undergo HSCT. 
6. Able and w illing to use an effective method of  contracepti on (see Section 11.1) from the 
signing of the informed consent through the Primary Study Period , for male and female 
subjects with reproductive  potential. 
5.2 Exclusion Criteria 
1. Previous history of autologous or allogeneic HSCT or solid organ transplantation . 
2. Pregnant or breastfeeding female . 
3. -globin allelic variants associated with clinically significant altered o xygen affinity (see 
Appendix 2 ). 
4. Medical contraindication to mobilization , apheresis or conditioning . 
5. ANC ≤1,000/µL . 
6. Abnormal liver function tests defined b y: 
• direct bilirubin ≥ 3x ULN, or  
• AST or ALT ≥3x ULN  
7. Renal dysfunction as defined by serum creatinine ≥2.0 mg/dL . 
8. Bridging fibrosis, liver cirrhosis, or active hepatitis based on liver biopsy obtain ed in 
previous 12 months or at S creening. 
9. Massive splenomegaly (based on Investigator ’s clinical judgement) . 
10. Treatment with p rohibited medications in previous 30 days. 
11. Clinically significant, active bacterial, viral, fungal, or parasitic infection  (based on 
Investigator ’s judgement ). 
12. Diagnosis of HIV or evidence of active hepatitis B virus  (HBV) or hepatitis C virus (HCV) 
infection based on S creening laboratory testing . 
13. Karnofsky performance scale ≤60 . 
14. Corrected DLCO ≤5 0% of predicted or clinically -significant res trictive lung disease based 
on Screening pulmonary function tests (PFTs) . 
15. Congestive heart failure (NYHA Class III or IV), unstable angina, uncontrolled arrhythmia, 
or left ventricular ejection fraction  (LVEF) <40%. 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 39 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 16. QTcF >500 msec based on S creening ECG . 
17. Cardiac T2* MRI <10 msec based on S creening MRI . 
18. History of significant ble eding disorder . 
19. Current diagnosis  of uncontrolled seizures . 
20. History of active malignancy in the past 5 years (non -melanoma skin cancer or cervical 
cancer in situ permitted) , any history of hematologic malignancy, or family history of 
cancer predisposition syndrome without negative testing result in the study candidate . 
21. History of or active alcohol or substance abuse that in the opinion of the Investigator  may 
interfere with study compliance . 
22. History of therapeutic non -adherence . 
23. Currently participating in another clinical trial using an investigational study medication, 
or participation in such a trial within 90 days or less than 5 half -lives of the in vestigational 
product prior to S creening visit . 
24. Previous treatment with gene therapy . 
25. Allergy or hypersensitivity to busulfan or study drug excipients (human serum albumin, 
DMSO, and Dextran 40) . 
26. Any other reason that, in the opinion of the Investigator  or Medical Monitor, would render 
the subject unsuitable for participation in the study . 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 40 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 6. INFORMED CONSENT  
At the screening visit, the Investigator  or designated personnel will explain to each subject the 
nature of the study, its purpose, the procedures, the expected duration, alternative therapies 
available, and the risks and potential ben efits of participation. The subject will receive an ICF, 
with the opportunity to ask questions, and will be informed that participation is voluntary, and that 
he/she can withdraw from the study at any time without any impact upon his/her future clinical 
care. After  this explanation and before any study -specific procedures are performed, the subject 
must voluntarily sign and date the  ICF. The subject will receive a copy of the signed and dated 
written ICF and any other written information required for the study. Each  subject will be 
re-consented at the time of any informed consent amendment, as applicable, and will be provided 
a copy of the revised consent form.  
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 41 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 7. STUDY METHODOLOGY  
Study procedures  are described in the following section and summarized in the Schedule of Events 
(see Appendix 1 ). Additional  detailed instructions will be provided in the Study Reference Manual, 
Imaging Manual, Laboratory Manual, and Study Cell Therapy Manual.  
7.1 Screening Visit s 
The objective of the screening visits is to identify subjects who meet the stated inclusion and 
exclusion criteria and who are willing and able to participate in the study. S creening will take 
approximately 6 weeks (+/ - 4 weeks), and may be performed across several visits.  
The following assessments and procedures will be performed  (see Section 9 for details on Study 
Assessment s): 
• Obtain signed and dated ICF and authorization document to use and disclose medical 
information (prior to performing any study -specific procedures ) 
• Obtain complete medical history , including concomitant medications; if the subject is not 
normally seen at the study center  it may be necessary to obtain medical records to confirm 
study eligibility  
• Collect demographic information  
• Review inclusion and exclusion cri teria 
• Assign subject number  
• Transfusion history  
• Assess AEs  
• Physical examination  
• Vital signs  
• Height 
• Weight 
• Karnofsky performance scale  
• Pregnancy test (for females with reproductive  potential only)  
• PFTs 
• Chest x-ray  
• Infectious disease marker panel  
• Clinical laboratory tests  
• ECG 
• Liver biopsy (unless performed within previous 12 months with proper medical 
documentation)  
• Comprehensive hemo globin analysis 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 42 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 • HbF quantification 
• Thalassemia -related disease  biomarkers  
• Endocrine lab testing  
• ECHO 
• Liver MRI  
• Cardiac MRI 
• SF-36 Survey 
7.2 Subject Enrollment  
Before enrollment, study site personnel must verify that the subject fulfills all eligibility criteria.   
Date of enrollment will be captured in the casebook as the date eligibility is confirmed by the 
Investigator . 
7.3 Mobilization, Apheresis, and Conditioning  
After meeting eligibility criteria and enrolling in the study, each subject will proceed to 
mobilization, a pheresis, and conditioning , which will span approximately 20 weeks (+/ - 8 weeks) 
and will be performed across several visits  as detailed below.  
7.3.1 CD34+ HSPC A pheresis  
Subjects who have signed the ICF and meet all the eligibility criteria will be scheduled for CD34+ 
HSPC mobilization . Sangamo should be contacted by the study center prior to scheduling CD34+ 
HSPC mobilization to ensure availability of the ST-400 manufacturing facility.  
7.3.1.1  G-CSF and Plerixafor Mobilization and Apheresis  
CD34+ HSPCs will be mobilized in  each subject followi ng G-CSF administration on Days 1 -6 of 
mobilization  (plus Day 7 if rescue treatment is collected on Day 7 ) and plerixafor administration 
prior to apheresis on Days 5 and 6 (plus Day 7 if rescue treatment is collected on Day 7). Timing 
of plerixafor adminis tration with respect to the start of apheresis may be approximately 10 to 
12 hours before apheresis; timing of both G -CSF and plerixafor is at the discretion of the 
Investigator . Within this timeframe, apheresis and mobilization may be started earlier and/ or 
discontinued earlier based on institutional practices, cell yields, and Investigator ’s judgement. 
Splenectomized subje cts will receive a reduced dose  of G-CSF, with further dose adjustment as 
necessary to target a WBC below 100,000 cells/ L. G-CSF and p lerixafor dosing, timing, or route 
of administration may be modified or discontinued at the discretion of the Investigator  if the WBC 
exceeds 100,000 cells/ L or if the subject becomes symptomatic . Detailed guidelines for 
administering  G-CSF and plerixafor  are provided in  the Study Cell Therapy Manual . 
It is strongly recommended that a vascular access consultation be obtained before the mobilization 
begins, and a temporary central catheter is inserted before the apheresis procedure. Sub jects should 
be hospitalized until the temporary central catheter has been removed at the conclusion of the 
apheresis procedures, or per study center  standard of care. Although peripheral access during 
apheresis might be an option in some cases, this pract ice is discouraged due to diminished yields 
of CD34+ HSPCs . 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 43 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 The mobilized cells  will be collected from each subject by apheresis o n Days 5 and 6 (+ Day 7 if 
needed to secure the rescue treatment) with a target of > 25 x 106 CD34+ HSPCs/kg ; however, 
lower yields are acceptable. The rescue treatment portion  must comprise  a minimum of 2.5 x 106 
CD34+ HSPCs/kg . 
If the first apheresis cycle does not mobilize the minimum number of  CD34+ HSPCs required for 
ST-400 drug manufacturing and for rescue treatment, the mob ilization procedure may be repeated. 
Selection of the timing of a second apheresis will be at the discretion of the Investigator  based on 
the subject’s clinical status, but may occur no sooner than 2 weeks after the  initial apheresis.  
The following assessments and procedures will be performed  within one week prior to 
administration of the first mobilizing agent (see Section 9 for details on Study Assessment s): 
• Review and record  concomitant medications  
• Assess AEs  (performed throughout  the visit) 
• Physical examination  
• Vital signs  
• Weight 
• Clinical laboratory tests  
• Pregnancy test (for females with reproductive potential only)  
• Transfusion log  (updated throughout study participation ) 
Prior to mobilization, it is recommended that subjects have a Hb level of ≥9.0 g/dL. Subjects may 
undergo a hypertransfusion procedure to achieve higher Hb levels at the discretion of the 
Investigato r. 
7.4 Gamete and Embryo Cryopreservation  
Busulfan treatment is associated with a high incidence of gonadal toxicity and infertility . All 
patients enrolled on this study will be counseled regarding the risk of gonadal toxicity with 
busulfan, and the strategy o f gamete cryopreservation. Each study subject will be able to choose 
whether he/she would like to pursue gamete cryopreservation. If gamete cryopreservation is 
chosen, it will be performed outside of the study. In some circumstances and at the 
recommendation of their treating physician, female participants may elect to undergo in vitro 
fertilization (IVF) using freshly obtained oocyte  gametes.  The associated costs borne by the 
Sponsor will be limited to the actual, reasonable cost of the gamete  cryopreservation procedures  
(and for some female  subjects, IVF), and storage of banked tissues and/or embryos for the duration 
of the subject’s participation in this  study. Scheduling of associated  procedures should be initiated 
as soon as possible after enrollment , and any invasive surgical procedures related to gamete and/or 
embryo cryopreservation  should be completed by approximately  30 days prior to ST -400 infusion  
at the Investigator’s discretion to allow for adequate healing . 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 44 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 7.5 Baseline Assessments  
The following assessments and procedures will be performed within 2 weeks prior to conditioning 
with IV busulfan  (see Section 9 for details on Study Assessment s):  
• Review and record concomitant medications  
• Assess AEs  
• Physical examination  
• Vital signs  
• Weight 
• Karnofsky performance scale  
• Pregnancy test (for females with reproductive  potential only , within one week prior to first 
busulfan infusion ) 
• Clinical laboratory tests  
• ECG 
• BCL11A gene modification assay  
• HbF quantific ation 
• Immunological assay  
• Transfusion log  
• Thalassemia -related disease  biomarkers  
• Endocrine lab testing 
• Sampling for Potential Retrospective Analysis in the Event of Hematological Malignancy  
• F-cell percentage  
• DXA 
• SF-36 Survey 
• Bone marrow aspiration  
If more than 30 weeks will elapse between the start of the Screening visit and the Baseline visit, 
the Investigator  will confirm that the subject still meets all inclusion/exclusion criteria. At the 
Investigator ’s discretion, repeat testing may be performed as appropriate. At a minimum,  the 
following tests will be repeated at Baseline:  
• Pulmonary function tests (PFTs)  
• Chest X-ray  
• Echocardiogram (ECHO)  
Results should be recorded in the eCRF, and the Investigator  should assess results against the 
appropriate study inclusion and exclusion criteria to confirm the subject continues to meet study 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 45 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 eligibility before pro ceeding to C onditioning. This assessment should be documented in source.   
Subjects who no longer meet eligibility criteria will be discontinued from study participation.  
7.6 Conditioning   
A subject will not proceed to conditioning  with IV busulfan until a sufficient quantity of rescue 
treatment is obtained and ST-400 is manufactured, passes quality control and release testing, and 
is confirmed as received at the clinical site . 
After release of  ST-400 for clinical use, subjects will be admitted to the hospital for central venous 
catheter insertion and to begin IV busulfan  in a dedicated transplant unit . Subjects will be 
hospitalized in accordance with study center standard  procedures for recipie nts of HSCT . The 
estimated duration of the hospitalization is approximately 2 to 4 weeks, but the actual duration 
shall be determined by the Investigator  depending upon a subject’s clinical course.  
Seizure prophylaxis during IV busulfan is strongly recommended. Iron -chelating agents should be 
discontinued 2 weeks prior to IV busulfan, and may be restarted after successful hematopoietic 
reconstitution or at the discretion of the Investigator. Subjects will receive a myeloablative dose 
of busulfan (3.2 mg/kg/day ; administered IV via central venous catheter either once daily or every 
6 hours) for 4 days (total dose of 12.8 mg/kg) . For detailed in structions for administering IV 
busulfan refer to the Study Cell Therapy Manual . 
After the first dose , the IV busulfan  dose will be adjusted based upon pharmacokinetic s ampling 
and study center practices to target an AUC of 4,0 00-5,000 µmol*min for daily dosing or an AUC 
of 1,000-1,250 µmol*min for every 6 hour dosing for  a total regimen target AUC of 16,000-20,000 
µmol*min. IV busulfan pharmacokinetic targeting may be modified for subsequent subjects based 
on experience with previous subjects after discussion with the SMC. Therapeutic drug monitoring  
to determine clearance  of busulfan after 4 days of dosing is complete  is not required but may be 
performed at the discretion of the Investigator  in accordance with study center  practices.  Please 
refer to Section 9.3 for additional information on concomitant medications . 
The following assessments and procedures will be performed daily during conditioning  (see 
Section 9 for details on Study Assessment s): 
• Review and record concomitant medications  
• Assess AEs  
• Physical examination  
• Vital signs  
• Transfusion log  
• Samples for central laboratory analysis (“Clinical laboratory tests”) should be collected at 
least once during conditioning, with timing at the discretion of the Investigator  
Additional safety precautions, assessments, and treatments conducted as part of standard transplant 
medical care  outside of those specified in this study (e.g., clinical laboratory testing, immune 
function testing, cytomegalovirus (CMV) prophylaxis, etc.) will be undertaken as per 
Investigator’s judgement and study center practice. These include, but are not limited to, 
antimicrobial prophylaxis, RBC transfusion to maintain hemoglobin at levels deemed appropriate 
for the subject, and platelet transfusions a s needed. 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 46 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 7.7 Day 0 (ST -400 Infusion)  
The ST-400 drug product will be infused n o sooner than 72 h ours after the final dose of IV busulfan  
in the conditioning  phase. For detailed instructions for thawing and administer ing ST-400 see the 
Study Cell Therapy Manua l. 
The target cell dose of ST -400 to be administered is 10  x 106 cells/kg body weight and the 
minimum cell dose required is 3.0 x 106 cells/kg body weight  (cell dose is determined by the yield 
during apheresis). Subjects may receive more than one lot of ST -400 if multiple apheresis cycles 
were required to ensure the minimum cell dose. No dose modifications of ST -400 are possible 
within an individual subject  since this is a single infusion study.  G-CSF may be administered 
post-transplant as per the Investigator ’s judgement.  
The following assessments and procedures will be performed (see Section 9 for details on Study 
Assessment s): 
• Review and record concomitant medications  
• Assess AEs  
• Physical examination  
• Serial vital signs as detailed in the Study Reference Manual  
• Clinical laboratory tests  
• ECG 
• HbF quantification 
• Transfusion log  
• Thalassemia -related disease  biomarkers  
Vital signs (temperature, heart rate, respiratory rate, blood pressure, and oxygen saturation) will 
be monitored before, during, and after the infusion as detailed in the Study Referenc e Manual, and 
as needed to maintain good clinical care in accordance with study center practice . 
Additional safety precautions, assessments, and treatments conducted as part of standard 
post-transplant medical care outside of those specified in this study (e.g., clinical laboratory 
testing, immune function testing, cytomegalovirus ( CMV) prophylaxis, G -CSF administration, 
etc.) will be undertaken as per Investigator ’s judgement and study center  practice. This includes, 
but is not limited to, antimicrobial prophylaxis, G -CSF administration, RBC transfusion to 
maintain hemoglobin at levels deemed appropriate for the subject, and platelet transfusions as 
needed. 
7.8 Days 7 (+/-1 day), 14 (+/-1 day), 21 (+/-1 day), 28 (+/-1 day), 35 (+/- 2 days), 42 (+/ -2 
days), 56 (+/-5 days), and 90 (+/-7 days); and Weeks 26 , 39, and 5 2 (+/- 14 days) 
(Primary Study Period ) 
The following assessments and procedures will be performed at each visit unless stated otherwise  
(see Section 9 for details on Study Assessment s):  
• Review and record concomitant medications  
• Assess AEs  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 47 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 • Physical examination  
• Vital signs  
• Karnofsky performance scale  (Weeks 26 and 52) 
• Pregnancy test (for females with reproductive potential only ; Days 28 , 56 and 90, and 
Weeks 26, 39, and 52)  
• PFTs (Week 52) 
• Clinical laboratory tests  
• ECG (Day 28; Weeks 26 and 52 ) 
• Screening  for Malignancy (Days 28, 35, 42, 56, and 90; Weeks 26, 39, and 52 ) 
• BCL11A gene modification assay ( Days 14, 28, 42, 56, and 90; Weeks 26, 39, and 52 ) 
• HbF quantific ation (Days 14, 28, 42, 56, and 90; Weeks 26, 39, and 52 ) 
• Immunological assays ( Day 90; Week 52) 
• Transfusion log  
• Thalassemia -related disease biomarkers ( Day 90; Weeks 26, 39, and 52 ) 
• Endocrine lab testing  (Week 52) 
• Subset analysis of gene modification ( Week 39) 
• Sampling for Potential Retrospective Analysis in the Event of Hematological Malignancy  
(Day 90; Weeks 26, 39, and 52 ) 
• F-cell Percentage  (Days 28, 56, and 90; Weeks 26 and 52)  
• ECHO (Week 52) 
• Liver MRI ( Week 52) 
• Cardiac MRI ( Week 52) 
• DXA (Week 52) 
• SF-36 Survey (Weeks 26 and 52 ) 
• Bone marrow aspiration : 
o Day 90: can be waived at the discretion of Investigator ;  
o Bone marrow aspirate may be performed at either the Week 26 or the Week 39 
visit; it should not be performed at both.  Both of these procedures (at both Week  26 
and Week 39) may be waived at the Investigato r’s discretion.   
o Week 52 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 48 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 7.9 Weeks 65, 78, 91, 104, 11 7, 130, 143, and 156 (+/- 14 days) ( Follow-up Study Period ) 
The following assessments and procedures will be performed at each visit unless stated otherwise  
(see Section 9 for details on Study Assessment s):  
• Review and record concomitant medications  
• Assess AEs  
• Physical examination  
• Vital signs  
• Karnofsky performance s cale (Weeks 104 and 15 6) 
• Clinical laboratory tests  
• ECG (Weeks 104 and 15 6) 
• Screening for Malignancy  
• BCL11A gene modification assay ( Weeks 78, 104, 130, and 156) 
• HbF quantific ation 
• Immunological assays ( Weeks 65 and 11 7) 
• Transfusion log  
• Thalassemia -related disease biomarkers ( Weeks 78, 104, 130, and 15 6) 
• Endocrine lab testing (Weeks 65 and 117)  
• Subset anal ysis of gene modification (Weeks 91 and 14 3) 
• Sampling for Potential Retrospective Analysis in the Event of Hematological Malignancy  
(Weeks 78, 104, 130, and 15 6) 
• ECHO (Weeks 104 and 15 6) 
• Liver MRI (Weeks 104 and 156)  
• Cardiac MRI (Weeks 104 and 156)  
• DXA (Weeks 104 and 156)  
• SF-36 Survey (Weeks 104 and 156)  
• Bone marrow aspiration  (Week 104 ) 
7.10 Early Termination Visit  
Subjects who discontinue from the study prematurely will be asked to r eturn to the study site for 
an early termination visit  (ETV). It is at the discretion of the Investigator , in consultation with the 
Medical Monitor, to waive any procedure if the procedure has been performed wit hin the standard 
interval of scheduled study visits per protocol  or if the procedure would place undue burden on the 
subject. 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 49 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 The following assessments and procedures will be performed at the ETV (see Section 9 for details 
on Study Assessment s): 
• Review and record concomitant medications  
• Assess AEs  
• Physical examination  
• Vital signs  
• Karnofsky performance scale  
• Pregnancy test (for females of reproductive potential only)  
• Clinical laboratory tests  
• ECG 
• Screening for Malignancy  
• BCL11A gene modification assay  
• HbF quantific ation 
• Immunological assays  
• Transfusion log  
• Thalassemia -related disease biomarkers  
• Endocrine lab testing  
• Sampling for Potential Retrospective Analysis in the Event of Hematological Malignancy  
• ECHO 
• Liver MRI  
• Cardiac MRI  
• SF-36 Survey 
• Bone marrow aspiration  
7.11 Rescue Treatment  
Should a subject experience  delayed hematopoietic reconstitution or graft failure with aplasia, the 
subject will receive the rescue treatment consisting of  unmodified , autologous CD34+ HSPCs , and 
an SMC safety review will be performed  under the study suspension rules . Delayed hematop oietic 
reconstitution or g raft failure with aplasia is defined as persistent ANC <500 cells/µL through 
Day 42 post-infusion. The rescue treatment may be administered  at any time  after ST-400 infusion  
if needed at the discretion of the Investigator  based on clinical indications for subject safety . 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 50 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 7.12 Unscheduled Visits  
Unscheduled visits may be performed at any time during the study w henever necessary to assess 
or to follow -up on AEs, or as deemed necessary by the Investigator . Evaluations and procedures 
to be performed at unscheduled visits will be at the Investigator ’s discretion in consultation with 
the Sponsor, and may be based on those l isted in the Schedule of Events ( see Appendix 1 ). 
7.13 Subject Withdrawal and Discontinuation from Study  
Subjects may withdraw or should be discontinued from the study for any of the following reasons:  
• Request by the subject to withdraw . 
• Request of S ponsor or Investigator  if he or she thinks the study is no longer in the best 
interest of the subject . 
• Pregnancy of subject prior to IV busulfan  infusion. 
• Subject judged by the Investigator  to be at significant risk of failing to comply with the 
provisions of the protocol as to cause harm to self or seriously interfere with the validity 
of the study results . 
• At the discretion of the institutional review board ( IRB), Office for Human Research , 
regulatory authority (e.g., FDA), Investigator , or Sponsor. 
Subjects will be strongly encouraged to continue and comply with follow -up safety evaluations. If 
a subject withdraws consent or discontinues from the study post -study treatment, a conference 
between the Investigator  and Medical Monitor will take place to ensure and document that the 
subject understands the importance of the study follow -up and that the study treatment cannot be 
revised even if a subject drops out of the study follow -up. If the subject agrees, a reduced follow -up 
testing schedule may be arr anged including telephone call and safety labs to assess 
treatment -related AEs and disease status.  
7.14 Long-term Follow-up Protocol for Adverse Effects of Gene Therapy  
All subjects will be followed for a total of 3 years after ST -400 dosing under this protocol .  
To assess long -term safety, subjects will be asked to participate in a separate long -term follow -up 
(LTFU) study after they complete this study. The total combined (current and LTFU studies) 
follow up period will last 15 years. The LTFU study will be co nducted by Bioverativ Therapeutics 
Inc. (Sanofi) as both companies are developing equivalent gene -edited cell products, ST -400 for 
the treatment of transfusion -dependent β -thalassemia and Sanofi BIVV003 for the treatment of 
sickle cell disease.  
A separate informed consent will be obtained for subjects to be followed in a LTFU study.  
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 51 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 8. STUDY PRODUCT AND OTHER MEDICATIONS  
8.1 ST-400 
ST-400 is composed of autologous CD34+ HSPCs  that are genetically modified ex vivo at the 
erythroid-specific enhancer  of the BCL11A gene by the ZFN mRNAs SB-mRENH1 and 
SB-mRENH2 to boost endogenous production of HbF . 
Component  Unit Formula  
BCL11A erythroid-specific enhancer modified 
CD34+ HSPCs  10 million cells/mL  
Cryopreservation Buffer (CryoStor® CS10) 
containing 10% Dimethyl Sulfoxide (DMSO)  1 mL 
ST-400 is cryopreserved in  50 mL Cryo MACS® freezing bags (fill volume of approximately 1 0 to 
20 mL; total cell count of approximately 1.0  x 108 to 2.0 x 108 cells) using a controlled rate freezer . 
Multiple freezing bags are used if cell yield exceeds the capacity of a single bag. Infusion bag s are 
stored in vapor phase  liquid nitrogen ( at ≤ -150oC) at the manufacturing facility until they are ready 
to be shipped to the clinical study center.  
ST-400 will be shipped to clinical study sites in a liquid nitrogen (LN2) Dry Shipper with a 
temperature  monitoring device. A Certificate of Analysis (COA) and Clinical Certificate of 
Analysis (CCOA) will accompany each shipment. Each freezing bag will carry a label that 
identifies the product name, sponsor/manufacture r, protocol number, date of manufacture, subject 
ID number, subject initials, lot number,  bag number,  “FOR AUTOLOGOUS USE ONLY” , and 
standard mandated langu age for products for investigational us e. Additional details on the ST -400 
investigational product and infusion protocol are provided in the Study Cell Therapy Manual.  
8.1.1 Inventory, Storage, and Handling  
Upon receipt and prior to administration , the infusion bag(s) are stored in the LN2 Dry Shipper or 
freezer capable of maintaining ≤ -150oC (with temperature monitoring) .  
No individuals other than those who are authorized by the Investigator  to administer  the study drug 
shall have access to the study drug. The Investigator  agrees not to supply study drug to any person 
other than study personnel and subjects in this study.  
The study center is required to maintain complete records of all study drug received during this  
study, as well as of any study drug that is dispensed  or disposed of . At the conclusion or termination 
of this study, destruction of all drug supplies must be pre -approved and coord inated with Sangamo  
(see the Study Cell Therapy Manual  for additional details) . 
8.1.2 Administration  
ST-400 shall be infused  no sooner than 72 hours after the final dose of IV busulfan  in the 
conditioning  phase.  
Following thaw, ST-400 will be infused per detailed instructions set forth in the Study Cell 
Therapy Manual . 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 52 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 At the time of ST-400 receipt , 2 individuals will independently confirm that the information  from 
the study drug  is correctly matched to the subject.  
Immediately p rior to infusion , 2 individuals will independently and in the presence of the subject 
confirm that the info rmation from the study drug  is correctly matched to the subject . 
8.1.3 Precautions  
Emergency medical equipment and appropriate ly-trained medical personnel for the infusion of 
cryopreserved HSPC grafts must be available during the infusion in case the subje ct has an allergic 
response, severe hypotensive crisis, or any other reaction to the infusion.  
Vital signs (temperature, heart rate, respiratory rate , blood pressure , and oxygen saturation ) must 
be taken before , during, and after infusion  as detailed in the Study Reference Manual and in 
accordance with study center practice  (see Section 9).  
If a subject develops febrile neutropenia , veno-occlusive disease ( VOD), or other AEs related to 
the conditioning  procedure , appropriate medical management should be undertaken as per the 
Investigator ’s clinical judgement. AEs should be assessed and reported.  Additional information, 
guidance, and recommendations on post -transplant care are provided in the Study Cell Therapy 
Manual and Study Reference Manual.  
If possible contamination of the  ST-400 study drug is suspected, the study site will not proceed 
with infusion and will contact Sangamo.  
8.2 Intravenous Busulfan  
This protocol will exclusively use IV busulfan; oral administration will not be allowed.  
Busulfan is a bifunctional alkylating age nt that causes DNA -DNA crosslinks and triggers cell 
apoptosis. Because it specifi cally affects non -dividing stem  cells in the bone marrow, busulfan is 
used either alone or in combination with other agents (e.g., cyclophosphamide) as the 
myeloablative conditioning agent of choice for allogenic and autologous HSCT.  
8.2.1 Inventory, Storage, and Handling  
Please refer to package insert.  
8.2.2 Administration  
Please refer to package insert.  
For detailed guidance on IV busulfan therapeutic drug monitoring and dose adjustment based upon 
pharmacokinetic s ampling, refer to  the Study Cell Therapy Manual . 
8.2.3 Precautions  
Please refer to the busulfan package insert for complete safety information .  
8.3 G-CSF 
G-CSF is a 175 amino acid polypeptide that regulates the produc tion of granulocytes  within the 
bone marrow  and affects neutrophil progenitor proliferation, differentiation , and activation. In 
addition, G -CSF is a potent inducer of CD34+ HSPC  mobilization from the bone marrow into the 
bloodstream. G-CSF may be administered by either subcutaneous or IV route.  Pegylated G -CSF 
should not be used. G-CSF and fil grastim are used interchangeably  in this protocol.  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 53 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 8.3.1 Inventory, Storage, and Handling  
Please refer to package insert.  
8.3.2 Administration  
Please refer to package insert  and Study Cell Therapy Manual .  
8.3.3 Precautions  
Please refer to the G-CSF package insert for complete safety information.  
8.4 Plerixafor 
Plerixafor  reversibly inhibits binding of stromal cel l-derived factor -1-alpha (SDF -1α), expressed 
on bone marrow stromal cells, to the CXC chemokine receptor 4 (CXCR4), resulting in 
mobilization of CD34+ HSPCs  from bone marrow into peripheral blood. Plerixafor used in 
combination with G-CSF results in synerg istic increase in CD34+ HSPCs mobilization .  
8.4.1 Inventory, Storage, and Handling  
Please refer to package insert.  
8.4.2 Administration  
Please refer to package insert  and Study Cell Therapy Manual .  
8.4.3 Precautions   
Please refer to the plerixafor package insert  for complete safety information .  
8.5 Concomitant Medication  and Supportive Care  
It is recommended that subjects have completed their routine vaccinations (hepatitis A , HBV, 
pneumococcus, influenza , and tetanus diphtheria booster) at least 30 days prio r to the conditioning  
procedure .  
It is further recommended that subjects receive a ll supportive therapy and standard medical care 
deemed appropriate by the Investigator  and per study center standard  procedure s. This includes , 
but is not limited to , antimicrobial prophylaxis , G-CSF administration, RBC transfusion to 
maintain hemoglobin  at levels deemed appropriate for the subject , and platelet transfusions as 
needed. Seizure prophylaxis during IV busulfan  is strongly recommende d. Iron-chelating agents 
should be discontinued 2 weeks prior to b usulfan infusion, and may be restarted after successful 
hematopoietic reconstitution or at the discretion of the Investigator . 
Concomitant medications such as acetaminophen or metronidazole should be avoided in the 
peri-transplant period as they may reduce the clearance of busulfan and thus cause excessive 
busulfan toxicity. Additional guidance on busulfan drug interactions with commonly used 
concomitant medications is provided in the Study Cell Therapy Manual . 
Potential s ide effects that are associated with DMSO following ST -400 infusion may include 
transient fever, chills, and/or nausea . Serious allergic reaction in association with ST -400 
administration has been reported (refer to Section 1.9.1 for additional details).  Pre-medication or 
post-infusion treatment with acetaminophen , diphenhydramine hydrochloride (Benadryl) , and 
glucocorticosteroids (such as hydrocortisone) , may be administered  and repeated  as needed  per 
site practice and Investigator’s judgment .  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 54 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 Following the conditioning  procedure, subjects will be isolated in single rooms to reduc e the risk 
of infections, and appropriate precautions will be taken while the ANC is <500 cells/ µL per the 
site’s standard practice , including anti -bacterial and anti -fungal prophylaxis. Standard -of-care 
treatment should be given to manage febrile neutrope nia. Routine monitoring for CMV 
re-activation and pre -emptive therapy should be performed as per study center practices. 
Medications for the prevention and treatment of hepatic VOD/sinusoidal obstruction syndrome, 
including ursodeoxycholic acid and defibro tide, may be administered at the discretion of the 
Investigator .   
The Investigator  will record on the concomitant medications page in the subject’s  electronic  case 
report form ( eCRF) all concomitant medications , including  over-the-counter medicinal products, 
dietary supplements, herbal medications, and medications given in treatment of AEs, taken by a 
subject from S creening throughout this study. 
8.6 Prohibited Medications   
The following medications are prohibited during the study as they may interfere with safety and 
or efficacy evaluation of the study drug, unless the Investigator  deems they are medically 
necessary:  
• Hydroxyurea  
• Erythropoietin or analogue  
• Systemic chemotherapeutic agents  
• Chronic systemic immunosuppressive med ications 
• Experimental medications  
• Any medication expected to alter HbF levels  
Subjects who have been treated with a prohibited medication in the 30 days prior to the screening 
visit are not eligible to participate in this study. Iron -chelating agents shoul d be discontinued 
2 weeks prior to conditioning with IV busulfan and may be restarted after successful hematopoietic 
reconstitution or at the discretion of the Investigator .  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 55 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 9. STUDY ASSESSMENTS  
9.1 Medical History  
A complete medical history, including prior surgeries and procedures, will be recorded for each 
subject at the screening visit.  
9.2 Demographics  
Demographic data on each subject (e.g. , age, gender, race, ethnicity, etc.) will be obtained at the 
screening visit.  
9.3 Concomitant Medications  
All history of medications taken prior to consent (prior medications) or at the time of or following 
consent (concomitant medications) for each subject will be record ed. Please refer to Section 8.6 
for the list of prohibited medications.  
9.4 Transfusion History  
History of RBC transfusions (mL packed RBC/kg, volume, date, etc.) will be recorded for each 
subject at the screening visit based on medic al documentation. A minimu m of 2 years of 
transfusion history prior to S creening is required to be eligible to participate in this study; however 
up to 3 years of history will be recorded if available.  
9.5 Physical Exam  
A physical examination will be conducted on each subject at the specified visits and will include 
at a minimum:  general appearance; head, eyes , ears, nose, and throat (HEENT) ; as well as  
cardiovascular, dermatologic, respiratory, gastrointestinal, musculoskeletal, and neurologic 
systems. Any clinically significant changes from previous visit s or new findings should be 
documented in the source and reported as an adverse event .  
9.6 Vital Signs  
Vital signs, including systolic/diastolic blood pressure, heart rate, temperature, respiratory rate, 
and oxygen saturation, will be recorded at the specified study visits for each subject.  Subject height 
will be measured at the Screening visit only.   Subject weight will be recorded at the Screening , 
Mobilization & Apheresis , and the Baseline visits.  
9.7 Karnofsky Performance Scal e 
The Karnofsky Performance Scale is a simple, widely-accepted tool for evaluating functional 
impairment  in patients . Each subject will be evaluated and scored at the specified visit using the 
Karnofsky Performance Status Scale Definitions Rating Criteria. Subjects with a score on the 
Karnofsky Performance Scale ≤60 at the screening visit are not eligible to participate in this study.  
9.8 Pregnancy Test  
Pregnancy testing will be conducted on all female subjects with reproductive  potential by serum 
or urine analysis at sp ecified visits. A female subject is considered of reproductive or childbearing 
potential, i.e., fertile, following menarche and until becoming post -menopausal (defined as no 
menses for 12 months without an alternative medical cause), unless permanently ste rile due to 
hysterectomy, bilateral salpingectomy or bilateral oophorectomy. Serum pregnancy testing should 
be conducted at the Screening,  Mobilization & Apheresis  (within one week prior to administration 
of the first mobilizing agent ) and Baseline visits (within one week prior to first busulfan infusion). 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 56 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 Urine pregnancy testing should be conducted at specified post -infusion visits (refer to 
Appendix  1). A positive or equivocal urine pregnancy test result will be confirmed with a serum 
pregnancy test.  If the result is positive, the Sponsor will be notified directly, and a Pregnancy and 
Partner Pregnancy Reporting Form  submitted  within 24 hours of discovery . Pregnant or 
breastfeeding subjects are  not eligib le to enroll into this study . 
9.9 Pulmonary Function Tests  (PFTs) 
Pulmonary function testing is a common method to evaluate respiratory function and oxygen 
transfer prior to myeloablative conditioning. Each subject will undergo PFT s at the screening  visit 
and Week 52. Subjects with c orrected DLCO ≤5 0% of predicted or clinically -significant restrictive 
lung disease are not eligible to participate in this study . If more than 30 weeks will elapse between 
the start of the Screening visit and the Baseline  visit, PFT will need to be repeated to confirm 
inclusion/exclusion criteria ( Section 7.5). 
9.10 Chest X-ray 
Chest X-ray (also known as AP radiograph of the chest) will be obtained on each  subject at the 
screening visit to evaluate the general health of the subject and eligibility for the study per the 
Investigator ’s clinical judgement.  If more than 30 weeks will elapse between the start of the 
Screening visit and the Baseline visit,  a chest X -ray will need to be repeated to confirm 
inclusion/exclusion criteria ( Section 7.5). 
9.11 Infectious Disease Panel  
Clinical laboratory testing for HIV, HBV, and HCV will be conducted at the screening visit. 
Subjects with a d iagnosis of HIV or evid ence of active HBV or HCV infection are not eligible to 
participate in this study.  
9.12 Clinical Labs  
Clinical laboratory testing will be conducted at the specified vi sits as detailed in Appendix 1 . 
Additional testing outside of what is specified in the protocol may be conducted as part of the 
apheresis procedure or post -transplant medical care as per Investigator ’s clinical judgement and 
study center practices.  Refer to Table 1 for the list of individual clinical laboratory tests that will 
be obtained in this study.  
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 57 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 Table 1: Clinical Laboratory Tests  
Hematology  
CBC with differential  
Reticulocyte count  
Peripheral smear  Serum Chemistry  
Sodium (Na)  
Potassium (K)  
Chloride (Cl)  
Carbonate (CO 32-) 
Calcium (Ca)  
Phosphate (PO 43-) 
Magnesium (Mg2+) 
BUN 
Creatinine  
Glucose 
LDH 
Uric acid 
Liver Function  
Bilirubin (total and direct)  
ALKP 
ALT 
AST 
Albumin 
Total protein  
Ferritin  Urine (with microscopic examination)  
Glucose  
Protein  
Bilirubin  
Blood 
pH 
Specific gravity  
Leukocyte esterase  
CBC = complete blood count; ANC = absolute neutrophil count ; ALKP = alkaline phosphatase; ALT = alanine 
aminotransferase (SGPT); AST = aspartate aminotransferase (SGOT); LDH = lactate dehydrogenase ; 
BUN = blood urea nitrogen .  
 
9.13 Electrocardiogram  (ECG) 
A 12-lead ECG will be obtained for each  subject at specified visits as a safety assessment to 
provide a baseline and to monitor for potential AEs on cardiac function/conduction.  
9.14 Liver Biopsy  
Liver biopsy is a routine procedure to detect occult liver disease that may predispose a subject to 
excessive busulfan toxicity. Subjects with b ridging fibrosis, liver cirrhosis, or active hepatitis 
based on liver biopsy are not eligible to participate in this study. Liver biopsy must be performed 
at Screening or in the 12 months prior to Screening with adequate medical documentation.  
9.15 Comprehensive Hemoglobin Analysis  
Comprehensive hemoglobin analysis will be conducted on all subjects at Screening to assess for 
HBA1/2 (α -globin) and HBB (β -globin) mutations and/or deletion/duplication analysis, and HBD 
(δ-globin) and HBG1/2 (γ -globin) mutations. This testing will provide m olecular confirmation and 
characterization of the -thalassemia  genotype. Subjects who are found to have -globin allelic 
variants associated with clinically signific ant altered oxygen af finity are not eligible to participate 
in this study (refer to Appendix 2 ). 
9.16 Screening for Potential Hematological Malignancies  
Although ST -400 is designed to have highly precise gene modification without insertional 
mutagenesis, the risk for development of a hematological malignancy remains undefined. 
Therefore, subjects will be  closely monitored throughout the study for the potential development 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 58 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 of hematopoietic malignancies using clinical history, physic al exams, laboratory assessments, and 
bone marrow aspirations for : 
• new or worse ned unexplained lymphadenopathy;  
• new or worsened unexplained hep atosplenomegaly;  
• unexplained WBC >30,000/ µL or ANC <500  cells/µL confirmed on repeat testing;  
• unexplained platele t count <5 0,000/µL confirmed on repeat testing;  
• clinical suspicion of malignancy, which may include unexplained and persistent symptoms of 
weight loss, anorexia, fatigue, fevers, headache, etc., based on Investigator ’s judgement; or  
• clinically-significant abnormality on bone -marrow aspiration suggestive of malignant 
transformation.  
If any of the above criteria are met at any time, the Sponsor will be notified and the subject will 
undergo a clinical work -up for the evaluation of malignancy  by a medical oncol ogist, which may 
include physical exam, laboratory testing, imaging, and bone marrow examination. In addition, an 
expedited analysis of markers of gene modification may be performed as described in Section 9.17. 
If the diagnosis of hematological malignancy is confirmed, a study suspension rule  will have been 
met, and all enrollment/dosing will be halted. An SM C will then convene and review all data to 
provide recommendations on the future of the study.  
In addition  to the clinical monitoring described above , for each subject the presence or absence of 
clonal populations will be assessed over time using high -throughput sequencing technology.  If 
“clonal dominance” within the indel pattern is detected (See Section 9.17), then the subject will 
undergo a clinical work -up for the e valuation of malignancy as above.    
9.17 BCL11A  Gene Modification Assay  
The proposed mechanism of action of ST -400 is to produce precise genetic modification of the 
erythroid-specific enhancer of the BCL11A gene through the use of engineered ZFNs.  The 
percentag e and durability  of gene modification at the BCL11A locus by ST -400 will be monitored 
at the time of product manufacturing and throughout the study. Analysis of the percentage of indels 
among all alleles, as well as dominance and frequency of any given ind el will be performed  using 
high-throughput sequencing technology.  
Hematopoietic “clonal dominance” based on indel analysis will trigger a clinical work -up for the 
evaluation of hematological malignancy (see Section 9.16).  “Clonal dominance” is defined 
using the following algorithm based  on the dominant indel detected:  
• If the dominant indel is ≥90% of the whole at any time in any bone marrow aspirate, 
unseparated whole blood or lineage -sorted blood samples , then “clonal dominance” has 
occurred;  
• If the dominant indel is ≥30%, then analysi s should be repeated on peripheral blood 
(unsorted, T -lineage and B -lineage) two more times with samples taken at 3-month intervals 
(ad hoc sampling to be conducted if necessary) . 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 59 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 o If on 1st or 2nd recheck the dominant indel is <30%, then “no clonal dominan ce” and 
return to monitoring per the routine schedule of events;  
o If on 1st recheck the dominant indel is ≥30% and <90%, and 2 nd recheck it is <50%, 
then “no clonal dominance” and return to monitoring per the routine schedule of events;  
o If on 1st recheck th e dominant indel is ≥30% and <90%, and 2 nd recheck is ≥50%, then 
“clonal dominance” has occurred.  
9.18 Subset Analysis of BCL11A  Gene Modification  
This assay is the same as the BCL11A Gene Modification Assay, but is performed on 
lineage-specific hematopoietic c ells, which have previously been sorted from the clinical sample.  
Hematopoietic “clonal dominance” based on indel analysis is defined using the same algorithm 
presented above (see Section 9.17).  
9.19 Sampling for Potential Retrospective Analysis in the Event of Hematological 
Malignancy  
ST-400 is designed to have highly -precise gene modification at the erythroid -specific enhancer of 
the BCL11A gene with minimal gene modifi cation detectable elsewhere in the genome. Clinical 
samples will be banked at specified time points, and in the event of a hematological malignancy, 
these samples may undergo additional retrospective analysis to better characterize the malignancy .  
These additional tests could include, but are not limited to, molecular translocation assays and 
analysis of off -target gene modification.  
9.20 HbF Quantification  
Genetic modification of the erythroid -specific enhancer of the BCL11A gene by ST -400 is 
expected t o boost endogenous levels of HbF by diminishing the inhibitory effect of BCL11A on 
transcription of the -globin genes. Peripheral blood samples will be collected in order to measure  
Hb fractions (A and F in g/dL) , and to quantify percent HbF for all subje cts at Screening, B aseline, 
and throughout this study.  
9.21 Immunological Assays  
Immunological assays (including , but not limited to lymphocyte subsets and quantitative 
immunoglobulins) will be conducted on peripheral blood samples collected from all subjects at 
Screening and post -conditioning  to evaluate hematopoietic reconstitution and immune 
recovery/function.  
9.22 Transfusion Log  
RBC transfusions will be closely monitored in this study. At the specified visits, any history of the 
occurrence or absence of RBC transfusions since the last visit should be eli cited and documented 
(mL PRBC/kg, volume, date, etc .). Therapeutic phlebotomy, if required, should also be 
documented on the transfusion log.  
Additionally, other blood products including, but not limited to, plat elets, intravenous 
immunoglobin (IVIG), plasma, and granulocytes that are administered during the study should be 
documented in the transfusion log.  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 60 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 9.23 Thalassemia -related Disease Biomarkers  
Thalassemia -related disease biomarkers will be tested throughout this study to evaluate the effect 
of ST-400 on erythropoiesis and iron overload. These exploratory  biomarker tests may include , 
but are not limited to , iron metabolism , erythropoietin, haptoglobin , and hepcidin levels. 
9.24 Endocrine Lab Testing  
Chronic iron overload in TDT leads to iron deposition in endocrine organs and subsequent 
endocrine dysfunction. Endocrine laboratory testing may include , but is not limited to , thyroid 
studies, IGF -1, morning cortisol,  adrenocorticotropic hormone ( ACTH), HbA1C, and vitamin D 
studies. 
9.25 Echocardiogram  (ECHO) 
A standard 2 -dimensional Doppler ECHO will be obtained at the specified visits to evaluate 
cardiac function, including left ventricul ar ejection fraction (LVEF), regional wall motion, and 
valvular morphology and function.  Subjects with LVEF <40% based on the S creening ECHO are 
not eligibl e to participate in this study.  If more than 30 weeks will elapse between the start of the 
Screening visit and the Baseline visit, a n ECHO  will need to be repeated to confirm 
inclusion/exclusion criteria ( Section 7.5). 
9.26 Liver MRI  
Liver disease and hepatomegaly are common co -morbidities of TDT due to increased RBC 
destruction and extramedullary erythropoiesis. The accelerated rate of erythropoiesis enhances 
dietary iron absorption from the gut, resulting in a chronic state of iron overload analogous to that 
seen in hereditary hemochromatosis. MRI is the standard method for eval uating iron deposition in 
the hepatocytes and Kupffer cells, revealing such hepatic iron overload as reduced R2-MRI 
assessed by FerriS can®. 
9.27 Cardiac MRI  
Cardiac abnormalities, in cluding heart failure and fatal arrhythmias, are major complications of 
TDT and frequent causes of death. Life -long transfusion therapy ameliorates cardiac pathology; 
however, TDT patients frequently develop cardiac hemosiderosis due to myocardial iron 
deposition. Cardiac MRI is the standard for evaluation  of iron deposition in the myocardium, 
revealing such myocardial iron overload as reduced myocardial T2* (T2 star). Subjects with 
myocardial T2*<10 msec at S creening are not eligible to participate in the study. 
9.28 DXA 
Osteoporosis and fractures are a common complication of TDT ( Vogiatzi et al., 2009 ). DXA is a 
convenient and reliable method to determine bone mineral density and to evaluate the presence of 
osteoporosis and fracture risk with low exposure to radiation.  
9.29 SF-36 Survey  
The SF-36 Survey is a quality -of-life questionnaire for assessing quality of life that is 
widely-accepted, validated, and easily administered. The SF -36 Survey relies upon patient 
self-reporting. It is comm only utilized in clinical drug development, and has been studied in patient 
populations with TDT  (Sobota et al., 2011 ). 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 61 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 9.30 Bone Marrow Aspiration  
Bone marrow aspiration is a routine clinical procedure to characterize hematopoiesis. TDT leads 
to profound erythroid hyperplasia with a high degree of immature cells and erythroid precursors 
of often bizarre morphologies. Bone marrow aspiration will be obt ained to evaluate changes from 
baseline in erythropoiesis and gene mod ification by ST -400, including in unsorted and lineage 
sorted subpopulations , and other exploratory analyses.  Bone marrow aspirates will be assessed at 
the clinical site for routine hematopathology review  to screen for potential malignant 
transformation  per the site’s standard clinical practice following transplantation . Unscheduled 
bone marrow aspiration may also be conducted at any time if clinically indicated, such as to 
evaluate the potential development of hematological malignancy . 
9.31 Percentage of F-cells 
F-cells are red blood cells that contain measurable amounts of HbF. Blood samples will be 
collected for analysis of percentage of  F-cells. 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 62 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 10. ADVERSE  EVENTS AND SERIOUS ADVERSE EVENTS 
AEs and SAEs will be monitored continuously during the study from the time that the subject has 
provided a signed ICF  through the subject’s last day of study participation. S ubjects will be queried 
and events will be  assessed at each clinic visit.  Subjects will be reminded to imm ediately report 
any AE to the Investigator . All AEs will be recorded in the subject’s CRF. The detailed description 
of the event will include appropriately graded severity of the AE and its re lationship to the study  
drug. 
10.1 Definitions of an Adverse Event  
An AE is any untoward medical occurrence associated with the use of a drug in humans,  whether 
or not considered drug -related. An AE can  include any of the following events that develop or 
increase in severity during this study: 
• Any sign, symptom, or physical examination finding that worsens in nature, severity, or 
frequency compared to baseline  status (i.e., prior to screening) , whether thought to be related 
or unrelated to the condition under st udy. 
• Any clinically significant laboratory abnormality or laboratory abnormality that requires 
medication or hospitalization . Abnormal laboratory results will be graded based on Common 
Terminology Criteria for Adverse Events ( CTCAE) 5.0 criteria. An asymptomatic Grade 1 or 
2 clinical laboratory abnormality should be reported as an AE only if it is considered clinically 
significant by the Investigator . A Grade 3 a nd 4 clinical laboratory abnormality  that represent s 
an increase in severity from baseline should be reported as an AE if it is not associated with a 
diagnosis already reported on the CRF.  
• All events associated with the use of ST-400, including those occurring as a result of an 
overdose, abuse, withdrawal  phenomena, sensitivity, or toxicity to ST-400. 
• Concurrent illness . 
• Injury or accident . 
A pre-existing condition is one that is present prior to screening , and is to be reported as part of 
the subject’s medical history. It should be reported as an AE only if the frequency, intensity, or the 
character of the condition worsens during study treatment.  
10.2 Classification  of an Adverse Event  
The Investigator  is responsible for determining  
• if the AE meets the criteria for an SAE,  
• the relationship of the AE to study treatment, and 
• the severity of the AE. 
10.2.1  Definition of a Serious Adverse Event  
A SAE is any AE  that in the view of either the Investigator  or Sangamo results in any of the 
following outcomes:  
• Death. 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 63 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 • Life-threatening threatening event  (i.e., an event that places the subject at immediate risk 
of death); however, this does not include an event that, had it occurred in a more severe 
form, might have caused death.  
• Inpatient hospitalization or prolongation of existing hospitalization . 
• Persistent or signifi cant incapacity or substantial disruption of the ability to conduct normal 
life functions . 
• Congenital anomaly/birth defect in the offspring of an exposed subject . 
• A medically important event.  
A medically important event is an AE that may not result in deat h, be life-threatening, or require 
hospitalization , but may be considered serious when, based upon appropriate medical judgment, 
the AE may jeopardize the subject and may require medical or surgical intervention to prevent one 
of the outcomes listed above. (Examples of such medical events include but are not limited to 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias , or convulsions that do not result in inpatient hospitalization .) 
10.2.2  Determination of R elationship of Adverse Event  to Study Treatment  
The Investigator  is responsible for classifying an AE and SAE as either Related or Not Related to 
ST-400 treatment.  Additional information will be collected on suspected relationship to study 
procedures (i.e ., apheresis) and/or other protocol -required medications (i.e., plerixafor, G -CSF, 
and busulfan).  
The following definitions should be considered when evaluating the relationship of AEs and SAEs 
to ST-400 treatment, study procedures , and/or other protocol -required medications.  
• Not related  
An AE will be considered “not related” to the use of the investigational product or study 
procedures if there is not a reasonable possibility that the event has been caused by the 
product under investigation or the study procedu res. Factors pointing toward this 
assessment include but are not limited to the lack of reasonable temporal relationship 
between administration of the product and the AE, the presence of a biologically 
implausible relationship between the product and the A E, or the presence of a more likely 
alternative explanation for the AE.  
• Related  
An AE will be considered “related” to the use of the investigational product or study 
procedures if there is a reasonable possibility that the event may have been caused by th e 
product under investigation or the study procedures. Factors that point toward this 
assessment include but are not limited to a positive rechallenge, a reasonable temporal 
sequence between administration of the product and the AE, a known response patter n of 
the suspected product, improvement following discontinuation or dose reduction, a 
biologically plausible relationship between the product and the AE, or a lack of an 
alternative explanation for the AE.  
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 64 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 10.2.3  Determination of Severity of Adverse Event 
Severity will be categorized by toxicity grade according to the Common Terminology Criteria for 
Adverse Events (CTCAE) Version 5.0. AEs not listed in the CTCAE Version  5.0 will be evaluated 
by using the following criteria:  
• Grade 1:  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
• Grade 2:  Moderate; minimal, local , or noninvasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living.  
• Grade 3:  Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indi cated; disabling; limiting self -care 
activities of daily living.  
• Grade 4:  Life-threatening consequences; urgent intervention indicated.  
• Grade 5:  Death related to AE.   
In the event of death, the cause of death should be recorded and reported as an SAE. “Death” is 
not the AE; “death” is an outcome. The term “death” should be reported as an SAE only if the 
cause of death is not k nown and cannot be determined. If an autopsy is performed, a copy of the 
autopsy report should be obtained if possible. The Investigator should make every effort to obtain 
and send death certificates and autopsy reports to Sangamo.  
10.2.4  Determination of E xpectedness of Adverse Event 
The expectedness of all AEs will be determined by the Sponsor according to the Investigator’s 
Brochure.  
10.3 Adverse Event Reporting  
All AEs should be reported starting from the time of signing of the ICF through the subject’s last 
study visit . The Investigator  is responsible for evaluating all AEs, obtaining supporting documents, 
and determining that documentation of the event is adequ ate. The Investigator  may delegate these 
duties to sub -Investigator s but must assure that these sub -Investigator s are qualified to perform 
these duties under the supervision of the Investigator . All AEs will be recorded in the subject’s 
CRF. 
10.4 Serious Advers e Event Reporting  
The reporting period for all SAEs starts from the time of signing of the ICF through the subject’s 
last study visit.  
All SAEs, whether or not considered to be associated with the administration of ST-400, must be 
reported immediately to Sangamo or its designees through the electronic data capture (EDC) 
system within 24 hours of the study staff  becoming aware  of the event.   A paper SAE Report Form 
may be used as a back -up option when the eCRF system is not functioning o r is inaccessible.  
Please refer to the Study Reference Manual for additional SAE reporting guidelines.  
Investigator must follow SAEs until resolution, stability, or return to baseline, even after the 
subject completes or discon tinues the study (i.e. , SAEs should not be left open). 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 65 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 The Medical Monitor will then advise the Investigator  regarding the nature of any further 
information or documentation that is required. Follow -up reports must be submitted within 
24 hours from the time that the additional information becomes availa ble. 
10.5 Specific Serious Adverse Event s 
In this study, the following AEs are considered medically important and must be reported as SAEs:  
• Malignancy  (excluding non -melanoma skin cancer and cervical cancer in situ)  
• Grade >3 hypersensitivity  reaction associated with administration of ST -400 according to 
CTCAE v5.0  
• Delayed hematopoietic reconstitution or g raft failure with aplasia  requiring the 
administration of the rescue aliquot  
10.6 Suspected Unexpected Serious Adverse Reactions  
A suspected unexpected ser ious adverse reaction (SUSAR) is any SAE that is assessed as both  
unexpected and, in the view of the Principal Investigator and/or the Sponsor, as related to the study 
treatment.   
The Sponsor  or its designee will submit SUSAR reports to appropriate regulat ory authorities, 
health authorities, and Investigator s as per local laws and regulations.  
The Investigator  is responsible for promptly notifying the IRB in accordance with local regulations 
of all SAEs.  
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 66 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 11. PROCEDURES FOR HANDLING SPECIAL SITUATIONS  
11.1 Pregnancy and Contraception Requirements  
Plerixafor and busulfan have been shown in animal studies to be teratogenic; busulfan has been 
shown to be genotoxic. The effects of administration of ST‑400 on the pregnant female or the 
developing fetus are unknown. Thus , male subjects and female subjects with reproductive or 
childbearing potential must agree to use an effective method of contraception during the study.   
Male and f emale subjects with reproductive potential must agree to use contraception from  the 
signing the informed consent through the Primary Study Period.  
Male subjects are considered fertile after puberty unless permanently sterile by bilateral 
orchidectomy. Female subjects are considered of reproductive or childbearing potential, i.e., 
fertile, follo wing menarche and until becoming post -menopausal (defined as no menses for 
12 months without an alternative medical cause), unless permanently sterile due to hysterectomy, 
bilateral salpingectomy or bilateral oophorectomy.  
The following are considered effective methods of birth control:  
• Combined (estrogen and progestogen containing) hormonal contracept ion associated with 
the inhibi tion of ovulation:  
o Oral, or  
o Intravaginal, or  
o Transdermal  
• Progestogen -only hormonal contracepti on associated with inhibition of ovulation:  
o Oral, or 
o Injectable, or  
o Implantable  
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion  
• Vasectomized partner  (provided that  partner is the sole sexual partner)  
• Sexual abstinence  (refraining from heterosexual intercourse  for the duration of the 
protocol-defined period ) 
• Male condom with spermicide AND cervical cap  
• Male condom with spermicide AND diaphragm  
• Male condom with spermi cide AND cervical sponge  
Females will be tested for pregnancy  at specified visits (see Section 9.8). 
• Pregnant females will not be enrolled in the study.  
• Female subje cts enrolled in the study who become pregnant prior to myeloablation/ ST-400 
administration will be discontinued from further study procedures to avoid potential risks 
to the developing fetus (see Section 7.13). 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 67 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 • Female subjects enrolled in the study who become pregnant following ST-400 
administration will be allowed to continue in the study but will not undergo any scheduled 
procedures considered by the Investigator  and Sponsor to have potential risk to the 
developing fetus.  
Pregnancies or pregnancies of partners occurring in subjects during this study are to be reported 
on the Pregnancy Reporting Form. In general, it is expected that pregnancies will be reported in  
the same timeframe as SAEs. Regardless of whether the subject has discontinued participation in 
the study, the course of all pregnancies will be followed to partum at minimum.  
Congenital abnormalities/birth defects in the offspring of subjects should be reported as an SAE if 
conception occurred during this study.  
11.2 Medical Emergency  
In a medical emergency requiring immediate attention, study site staff will apply appropriate 
medical intervention according to current standards of care. The Investigator  (or designee) should 
contact the study’s Medical Monitor or designee . Refer to Page 2 of this protocol  for complete 
contact information  for the Medical Monitor .  
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 68 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 12. SAFETY MONITORING  
An external, independent SMC with appropriate medical and scientific expertise in TDT and 
HSCT will provide oversight of the study for patient safety. A Chair will be appointed and minutes 
will be generated and retained for each of the SMC meetings.  
The SMC will be convened after the 3 sentinel subjects have achieved successful hemat opoietic 
reconstitution based on the criteria defined, and subsequently approximately every 3 -6 months 
during the study period to monitor safety and tolerability of ST -400. The SMC may be convened 
earlier or at any time if deemed necessary by the Sponsor o r SMC. Specifically, the SMC will be 
convened if a study suspension rule (see Section 4.8) is met. When convened, the SMC will 
evaluate all data available to provide recommendations on changes to the study and whether 
enrollment or dosing should continue. As a component of their ongoing review of safety data, the 
SMC will also provide recommendations on any ST 400 -related AEs that should be characterized 
as dose-limiting toxicities of ST -400 treatment.  
The SMC oversaw the safety of study participants from 29th March 2018 till 18th December 2020. 
Afterward , the safety oversight was transferred to a joint Safety Monitoring Team (SMT) 
composed of members of Sangamo and San ofi considering both companies are developing 
equivalent gene -edited cell products (ST -400 and BIVV003) for 2 different indications (TDT and 
SCD), respectively.  
The SMT is a cross -functional team composed of drug safety/pharmacovigilance, clinical 
development, clinical operations, and preclinical functions. The roles and responsibilities are 
detailed in the safety monitoring team charter.   
 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 69 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 13. STATISTICAL ANALYSIS  
This is an open -label, single -arm study, and analyses will be primarily descriptive in nature. No 
formal statistical hypothesis testing is planned. In general, continuous variables will be 
summarized by means, standard deviations, medians , minimum s and maximum s. Categorical 
variables will be summarized with counts and percentages per category. Some summaries may be 
presented as graphs. Additional details regarding the analysis of study data will be provided in the  
Statistical Analysis P lan. 
13.1 Analysis Populations   
Two analysis populations will be considered in this study .  The all-enrolled subjects population 
consists of all subjects enrolled into the study.  The safety population consists of all subjects who 
receive any amount of ST -400 in the study .  
13.2 Methods of Analysis  
The study outcome measures are described in Section 3. Full details of the statistical methods 
will be described in the Statistical  Analysis Plan.  
13.3 Analysis of Primary Outcome Measures  
The primary analysis of the primary outcome measure of this study is the incidence of AEs and 
SAEs in the safety population during the Primary Study Period, defined as the date of ST -400 
infusion through the date of the Week 52 study visit (or date of ETV for subjects withdrawin g 
prior to Week 52), inclusive.  
All reported AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). 
AE incidence will be summarized for all subjects. In addition, separate summaries will be 
generated for  serious adverse events , related adverse events and AEs by severity . Reported AEs 
starting prior to the Primary Study Period or starting after the Primary Study Period will be 
summarized or listed separatel y. 
Other safety outcome measures (including  results of laboratory tests [e.g., blood chemistry, 
hematology , and urinalysis]  and assessments [e.g., vital signs , ECG, ECHO, PFTs, bone marrow 
aspiration] , concomitant medications ) will be summarized, and shift s from baseline will be 
evaluated where appropriate. Duration of hospitalization following ST -400 administration and 
time to hematopoietic reconstitution  will be summarized.  
13.4 Analysis of Secondary Outcome Measures  
Baseline levels of Hb fractions (A and F in g/dL) and percent HbF  will be determined based on 
the last assessment on or prior to the date of first administration of IV busulf an. HbF levels and 
change from baseline will be summarized by study visit.  
Baseline annualized frequency  and volume of PRBC transfusions will be based on the 2  year 
period prior to Screening. Frequency and volume of transfusion will be annualized by study period 
and overall, and compared descriptively to the baseline values . 
13.5 Analysis of Exploratory  Outcome Measures  
Analysis de tails for the exploratory  outcome measures will be provided in the S tatistical Analysis 
Plan. 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 70 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 13.6 Other Study Data  
Other study data that will be summarized include subject disposition (for the Primary Study Period 
and for the overall study), demographic  and baseline characteristics,  use of concomitant 
medications,  study treatment administration  details, and time on study.  
13.7 Sample Size  
The sample size for this single -arm study is not based on providing statistical  power for hypothesis 
testing. However, for an AE with a true rate of 20%, a sample size of 6 subjects provides an 
approximately 74% likelihood that the event will be observed during the study.   
13.8 Interim Analysis  
Informal interim analyses may be performed at the Sponsor’s discretion . 
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 71 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 14. INVESTIGATOR  OBLIGATIONS  
The Investigator  will ensure that the study is conducted in compliance with the protocol, 
Declaration of Helsinki, ICH Guidelines for Good Clinical Practice (E6), and all regulatory and 
study center requirements, including those for subject privacy, informed consent, Institutional 
Review Board or Ethics Committee approval, and record retention.  
14.1 Informed Consent  
An Investigator  shall seek such consent only under circumstances that provide the prospective 
subject sufficient opportunity to consider whether or not to participate, and that minimize the 
possibility of coercion or undue influence. The information that is given to the subject or the 
representative shall be in language understandable t o the subject or the representative.  The 
Investigator  must keep each subject’s signed ICF on file for inspection by a regulatory authority 
at any time. 
Sangamo will provide the Investigator  with a template for the ICF. State and local laws and/or 
study cen ter requirements may require the disclosure of additional information in the ICF. The 
proposed ICF must be submitted to Sangamo prior to submission to the IRB or Independent Ethics 
Committee ( IEC) to ensure that it meets Sangamo standards for consent forms. The IRB or IEC 
must approve the ICF. A copy of the approved ICF must be submitted to Sangamo.   
14.2 Future Use of Stored Specimens  
With the subject’s approval and as approved by local IRBs, de -identified biological samples (i.e., 
residual content of samples collected for protocol -defined analyses) may be stored for future 
research. These samples could be used for further research into the effects of ST 400 and/or the 
causes of TDT, its complications a nd other conditions for which individuals with TDT are at 
increased risk, to improve treatment , or for assay development to address TDT or related 
indications .  
During the conduct of the study, an individual  subject can choose to withdraw consent to have 
biological specimens stored for future research. However, data from samples that have already 
been tested will not be removed from the study.  
14.3 Institutional Review Board and BioSafety Committee  
This protocol, ICF, and relevant substantive data are to be sub mitted to the appropri ate IRB and 
BioSafety Committee (BSC) for review and approval before the initiation of the study. 
Amendments to the protocol will also be submitted to the IRB and BSC (as appropriate) prior to 
implementation of the change. A letter do cumenting the IRB/BSC’s approval must be received by 
Sangamo prior to initiation of the study.   
14.4 Protocol Amendments  
Any changes to this protocol will be initiated by Sangamo in writing as a protocol amendment. 
The amendment must be submitted to the IRB together with a revised ICF, if applicable. Written 
documentation of IRB approval must be received before the amendment  can take effect.  
14.5 Subject Privacy  
Subject medical information obtained for the purposes of this trial is confidential, and disclosure 
to third parties other than those noted below is prohibited. Upon the subject’s request and written 
permission, medical in formation may be given to his/her personal physician or other appropriate 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 72 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 medical personnel responsible for the subject’s welfare. Data generated for this study must be 
available for inspection and/or provided  on request to representatives of national or l ocal health 
authorities, Sangamo, and the associated IRB/IEC.  
Release of research results or data that reveal subject names or other identifiers, such as 
photographs, audio, or videotapes, must be carried out in accordance with appropriate privacy 
regulations. Written authorization must be obtained from the subject and IRB/IEC prior to release 
of such information. Identifiable subject data may not be used for purposes of promoting the study 
drug. 
14.6 Other Reporting Obligations  
The Investigator  is also responsible for informing his/her IRB of the progress of the study and for 
obtaining annual IRB renewal. The IRB must be informed at the time of completion of the study. 
The Investigator  should provide his/her IRB (if required by the institution) with a su mmary of the 
results of the study.  
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 73 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 15. ADMINISTRATIVE  CONSIDERATIONS  
15.1 Study Documentation  
The Investigator  and study staff are responsible for maintaining a comprehensive and centralized 
filing system containing all study -related documentation. These files must be available for 
inspection at any time, shall be provided upon request, and should consist of the f ollowing 
elements:  
• Subject files containing the completed medical records, supporting source documentation, 
electronic CRFs, and the IRB /IEC approved ICF signed by subjects  
• Study files containing all versions of the IRB /IEC approved protocol with all amend ments, 
IRB approved ICFs, copies of all pre -study documentation, required forms,  and all 
correspondence to and from the IRB /IEC and Sangamo  
The Investigator  should maintain a list of appropriately qualified persons who are delegated to 
perform significant study-related activities. In addition, the Investigator  should maintain a 
signature sheet to document signatures and initials of all persons authorized to make entries and/or 
corrections on the source documents and electronic CRFs.  
15.2 Record Retention  
The Investigator  shall retain records required to be maintaine d under this part for a period of 
2 years following the date a marketing application is approved for the drug for the indication for 
which it is being investigated. If no application is to be filed or if the application is not approved 
for such indication,  the Investigator  shall retain these records until 2 years after the investigation 
is discontinued. However, these documents should be retained for a longer period if required by 
the applicable regulatory requirements or by an agreement with Sangamo. It is  the responsibility 
of Sangamo to inform the Investigator  as to when these documents no longer need to be retained.  
15.3 Case Report Forms  
The Investigator  is responsible for the quality of the data recorded on the CRF. The data recorded 
should be a complete an d accurate account of the subject’s record collected during the study.  
Clinical data will be recorded on CRFs provided by Sangamo. All forms must be legible and 
complete. The Investigator  must review all entries for completeness and correctness. When 
changes or corrections are made on any CRF, an audit trail will be generated to record date and 
time when a change is made, who made the change, and reason for the change as needed. The 
original entry should not be obscured.  
The Investigator agrees to complete and sign CRFs in a timely fashion, after completion of each 
subject visit, and make them available to the Study Monitor for full inspection. In addition, all data 
queries should be resolved promptly.  
15.4 Termination of the Study  
Sangamo retains the right to te rminate the study and remove all the study materials from the study 
site at any time. Specific instances that may precipitate such termination are as follows:  
• Completion of the study at an investigational site . 
• Investigator withdrawal from participation in study . 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 74 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 15.5 Study Monitoring  
Sangamo, as Sponsor of this study, is responsible to regulatory authorities for ensuring the proper 
conduct of the study with regard to protocol adherence and validity of the data recorded on the 
CRFs presented to t he regulatory authorities. Sangamo has therefore assigned a Medical Monitor 
and site monitor to this study. Their duties are to aid the Investigator and, at the same time, 
Sangamo in the maintenance of complete, legible, well -organized, and easily retrieva ble data. 
Individual st udy sites will be monitored by  Sangamo or a representative at appropriate intervals to 
assure satisfactory consenting process, data recording, and protocol adherence. To pe rform their 
roles well, the monitors must be given direct access to primary subject data (source documents) 
that support data entered onto the CRFs. The Investigator and staff are expected to cooperate and 
provide all relevant study documentation in detail at each site visit on request for review. Each 
study center will also be routinely monitored by telephone and/or by email to keep abreast of 
subject status and to answer questions.  
Regulatory authorities, the IRB /IEC, and/or Sangamo’s Clinical Quality Assurance group may 
request access to all source docum ents, CRFs, and other study documentation for on -site audit or 
inspection. Direct access to these documents must be guaranteed by the Investigator, who must 
provide support at all times for these activities.  
The Investigator or designated person should agr ee, as a minimum requirement, to record the 
following information in the subject notes:  
• Protocol identification number, brief description, or title of study  
• Date and statement that subject has signed ICF  
• All study follow -up visit dates  
• AE as described in Section 10 of this protocol  
Entries in the subject notes must contain the signature or initials of the person making the entries.  
15.6 Confidential Infor mation and Publication  
All information provided by Sangamo to the Investigator and any data or results generated in the 
performance of this clinical trial are considered confidential and remain the sole property of 
Sangamo. The Investigator shall maintain this information in confidence and use this information 
solely for in the conduct of the study unless otherwise expressly agreed to in writing by Sangamo.  
The Investigator understands and agrees that Sangamo shall have the right to use the data or results 
generated in the performance of the study for any purpose, including in registration documents for 
regulatory authorities in the U.S. or abroad, or for public dissemination in the form of papers, 
abstracts, posters, or other informational materials to be p resented at scientific meetings, or 
published in professional journals, or as a part of an academic thesis. The Investigator further 
understands and agrees that Sangamo shall have the right to first publication of the data or results 
of the study, which is intended to be a joint, multi -center publication of the study results made by 
Sangamo in conjunction with the Investigators from all appropriate investigational sites 
contributing data, analysis, and comments. Authorship of publications resulting from thi s study 
will be based on customary standards for attribution of authorship taking into consideration factors 
such as significance of contribution to the design of the study, analysis and interpretation of the 
data, and critical review of the publication. S ubsequent to the first publication of the study results 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 75 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 by Sangamo, the Investigator may publish the Investigator’s site -specific data or results. If the 
Investigator wishes to publish the Investigator’s site -specific data or results, a copy of such 
proposed publications, papers, abstracts, or other written materials, or an outline of any proposed 
oral presentations, shall be submitted to Sangamo for review at least 60 days prior to submission 
of such written materials for publication, or any proposed oral presentation. Sangamo shall have 
the right to review and comment on such written material or outline, and to confirm the accuracy 
of the data described therein by comparison with that collected during this study. In addition, 
Sponsor shall have the right t o require the Investigator to, and Investigator shall, remove 
specifically identified confidential information of Sangamo (other than the data or results of the 
study) and/or delay the proposed publication for an additional 60 days to enable Sangamo to fil e 
patent applications.  
15.7 Study Funding  
The costs necessary to perform the study will be agreed to by the Investigator and/or the 
management of the study facility, and will be documented in a separate financial agreement. All 
financial agreements will be sign ed by the Investigator and Sangamo.  
  
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 76 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 16. REFERENCES  
Baronciani D, Angelucci E, Potschger U, Gaziev J, Yesilipe k A, Zecca M, Orofino MG, Giardini 
C, Al-Ahmari A, Marktel S,  de la Fuente J, Ghavamzadeh A, Hussein AA, Targhetta C, Pilo F, 
Locatelli F, Dini G, Bader P, Peters C. Hemopoietic stem cell transplantation in thalassem ia: a 
report from the European Society for Blood and Bone Marrow Transplanta tion Hemoglobinopathy 
Registry, 2000-2010. Bone Marrow Transplant. 2016 Apr;51(4):536 -41. 
Bauer DE , Kamran SC, Lessard S, Xu J, Fujiwara Y, Lin C, Shao Z, Canver MC, Smith EC, 
Pinello L, Sabo PJ, Vierstra J, Voit RA, Yuan GC, Porteus MH, Stamatoyannopoulos JA, Lettre 
G, Orkin SH. An erythroid enhancer of BCL11A subject to genetic variation determines f etal 
hemoglobin level. Science. 2013 Oct 11;342(6155):253 -7.  
Brendel C, Guda S, Renella R, Bauer DE, Canver MC, Kim YJ, Heeney MM, Klatt D, Fogel J, 
Milsom MD, Orkin SH, Gregory RI, Williams DA. Lineage -specific BCL11A knockdown 
circumvents toxicities and  reverses sickle phenotype. J Clin Invest. 2016 Oct 3;126(10):3868 -
3878. 
Canver MC, Smith EC, Sher F, Pinello L, Sanjana NE, Shalem O, Chen DD, Schupp PG, Vinjamur 
DS, Garcia SP, Luc S, Kurita R, Nakamura Y, Fujiwara Y, Maeda T, Yuan GC, Zhang F, Orkin 
SH, Bauer DE. BCL11A enhancer dissection by Cas9 -mediated in situ saturating mutagenesis. 
Nature. 2015 Nov 12;527(7577):192 -7. 
Christianson SW, Greiner DL, Hesselton RA, Leif JH, Wager EJ, Schweitzer IB, Rajan TV, Gott 
B, Roopenian SC, Schultz LD. Enhanced hu man CD4+ T cell engraftment in beta2 -microglobulin -
deficient NOD -scid mice. J Immunol. 1997 Apr 15;158(8):3578 -86. 
Chang KH, Smith SE, Sullivan T, Chen K, Zhou Q, West JA, Liu M, Liu Y, Vieira BF, Sun C, 
Hong VP, Zhang M, Yang X, Reik A, Urnov FD, Rebar EJ , Holmes MC, Danos O, Jiang H, Tan 
S. Long-Term Reconstitution and Fetal Globin Induction upon BCL11A Gene Editing in Bone -
Marrow-Derived CD34(+) Hematopoietic Stem and Progenitor Cells. Mol Ther Methods Clin 
Dev. 2017 Jan 11;4:137 -148. 
Duong HK, Savani BN , Copelan E, Devine S, Costa LJ, Wingard JR, Shaughnessy P,Majhail N, 
Perales MA, Cutler CS, Bensinger W, Litzow MR, Mohty M, Champlin RE,Leather H, Giralt S, 
Carpenter PA. Peripheral blood progenitor cell mobilization for autologous and allogeneic 
hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow 
Transplantation. Biol Blood Marrow Transplant. 2014 Sep;20(9):1262 -73.  
Ferster A, Corazza F, Vertongen F, Bujan W, Devalck C, Fondu P, Cochaux P, Lambermont M, 
Khaladji Z, Sariban E. Transplanted sickle -cell disease patients with autologous bone marrow 
recovery after graft failure develop increased levels of fetal haemoglobin which corrects disease 
severity. Br J Haematol. 1995 Aug;90(4):804 -8. 
Galanello R, Origa R. Beta -thalassemia. Orphanet J Rare Dis. 2010 May 21;5:11.  
Giarratana MC, Rouard H, Dumont A, Kiger L, Safeukui I, Le Pennec PY, François S, Trugnan 
G, Peyrard T, Marie T, Jolly S, Hebert N, Mazurier C, Mario N, Harmand L, Lapillonne H, Devaux 
JY, Douay L. Proof  of principle for transfusion of in vitro-generated red blood cells. Blood. 2011 
Nov 10;118(19):5071 -9. 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 77 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 Gragert L, Eapen M, Williams E, Freeman J, Sp ellman S, Baitty R, Hartzman R, Rizzo JD, 
Horowitz M, Confer D, Maiers M. HLA match likelihoods for hematop oietic stem-cell grafts in 
the U.S. registry. N Engl J Med. 2014 Jul 24;371(4):339 -48. 
Hardison RC, Blobel GA. Genetics. GWAS to th erapy by genome edits? Science. 2013 Oct 
11;342(6155):206 -7. 
Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012 Jan 28;379(9813):373 -
83. 
Koren A, Profeta L, Zalman L, Palmor H, Levin C, Zamir RB, Shalev S, Blondheim  O. Prevention 
of β Thalassemia in Northern Israel - a Cost-Benefit Analysis.  Mediterr J Hematol Infect Dis. 2014 
Feb 17;6(1):e2014012.  
Locatelli F,  Kabbara N, Ruggeri A, Ghavamzadeh A, Roberts I, Li CK, Bernaudin F, Vermylen 
C, Dalle JH, Stein J, Wynn R, Cord onnier C, Pinto F, Angelucci E, Socié G, Gluckman E, Walters 
MC, Rocha V; Eurocord and European Blood and Marrow Transplantation (EBMT) group. 
Outcome of patients with hemoglobinopathies given  either cord blood or bone marrow 
transplantation from an HLA -identical sibling.  Blood. 2013 Aug 8;122(6):1072 -8. 
Modell B, Khan M, Darlison M, Westwood MA,  Ingram D, Pennell DJ. Improved survival of 
thalassaemia major in the UK and  relation to T2* cardiovascular magnetic resonance. J Cardiovasc 
Magn Reson. 2008 Sep 25;10:42 . 
Musallam KM, Sankaran VG, Cappellini MD, Duca L, Nathan DG, Taher AT. Fetal hemoglob in 
levels and morbidity in untransfused patients with β -thalassemia intermedia. Blood. 2012 Jan 
12;119(2):364 -7. 
Origa R. β -Thalassemia. Genet Med. 2017 Jun;19(6):609 -619. 
Paciaroni K, Lucarelli G. Hemopoietic stem cell transplantation failure followed by switch to 
stable production of fetal hemoglobin. Blood. 2012 Jan 26;119(4):1091 -2. 
Ribeil JA, Hacein -Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, Caccavelli L, 
Neven B, Bourget P, El Nemer W, Bartolucci P, Weber L, Puy H, Meritet JF, Grevent D, B euzard 
Y, Chrétien S, Lefebvre T, Ross RW, Negre O, Veres G, Sandler L, Soni S, de Montalembert M, 
Blanche S, Leboulch P, Cavazzana M. Gene Therapy in a Patient with Sickle Cell Disease. N Engl 
J Med. 2017 Mar 2;376(9):848 -855. 
Schultz LB, Chehab NH, Malik zay A, Halazonetis TD. p53 binding protein 1(53BP1) is an early 
participant in the cellular response to DNA double -strand breaks. J Cell Biol. 2000 Dec 
25;151(7):1381 -90. 
Shin, SI et al. Tumorigenicity of virus -transformed cells in nude mice is correlated specifically 
with anchorage independent growth in vitro. Proc Natl Acad Sci U S A. 72(11), 4435 -9 (1975). 
Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, 
Mangada J, Greiner DL, Handgretinger R. Human lymphoid and m yeloid cell development in 
NOD/LtSz -scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells . 
J Immunol. 2005 May 15;174(10):6477 -89. 
Smith EC, Luc S, Croney  DM, Woodworth MB, Greig LC, Fujiwara Y, Nguyen M, Sher F, 
Macklis JD, Bauer DE, Orkin SH. Strict in vivo specificity of the BCL11A erythroid enhancer. 
Blood. 2016 Oct 5; 128: 2338 -42. 
Sangamo Therapeutics , Inc.  
ST-400-01       CONFIDENTIAL AND PROPRIETARY   
Page 78 of 82  © 2021, Sangamo Therapeutics, Inc.   April 9th, 2021 Sobota A, Yamashita R, Xu Y, Trachtenberg F, Kohlbry P, Kleinert DA, Gi ardina PJ, 
Kwiatkowski JL, Foote D, Thayalasuthan V, Porter JB, Thompson AA, Schilling L, Quinn CT, 
Neufeld EJ; Thalassemia Clinical Research Network. Quality of life in thalassemia: a comparison 
of SF-36 results from the thalassemia longitudinal cohort to  reported literature and the US norms. 
Am J Hematol. 2011 Jan;86(1):92 -5. 
Stein S, Ott MG, Schultze -Strasser S, Jauch A, Burwinkel B, Kinner A, Schmidt M, Krämer A, 
Schwäble J, Glimm H, Koehl U, Preiss C, Ball C, Martin H, Göhring G, Schwarzwaelder K, 
Hofmann WK, Karakaya K, T chatchou S, Yang R, Reinecke P, Kühlcke K, Schlegelberger B, 
Thrasher AJ, Hoelze r D, Seger R, von Kalle C, Grez  M. Genomic instability and myelodysplasia 
with monosomy 7 consequent to EVI1 activation after gene therapy for chronic gran ulomatous 
disease. Nat Med. 2010 Feb;16(2):198 -204. 
Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, 
Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder -Scholl G, Plesa G, 
Hwang WT, Levine BL, June CH . Gene editing of CCR5 in autologous CD4 T cells of persons 
infected with HIV. N Engl J Med. 2014 Mar 6;370(10):901 -10. 
Thein SL, Menzel S, Lathrop M, Garner C. Control of fetal hemoglobin: new insights emerging 
from genomics and clinical implications. Hum  Mol Genet. 2009 Oct 15;18(R2):R216 -23. 
Vierstra J, Reik A, Chang KH, Stehling -Sun S, Zhou Y, Hinkley SJ, Paschon DE, Zhang L, Psatha 
N, Bendana YR, O'Neil CM, Song AH, Mich AK, Liu PQ, Lee G, Bauer DE, Holmes MC, Orkin 
SH, Papayannopoulou T, Stamatoyannop oulos G, Rebar EJ, Gregory PD, Urnov FD, 
Stamatoyannopoulos JA. Functional footprinting of regulatory DNA. Nat Methods. 2015 
Oct;12(10):927 -30. 
Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vi chinsky E, Olivieri N, Kirby M, 
Kwiatkowski JL, Cunningham M, Hol m IA, Lane J, Sch neider R, Fleisher M, Grady RW, Peterson 
CC, Giardina PJ; Thalassemia Clinical Res earch Network. Bone disease in thalassemia: a frequent 
and still unresolved problem. J Bone Miner Res. 2009 Mar;24(3):543 -57. 
Xu J, Peng C, Sankaran VG, Shao Z, Esrick EB, Chong BG, Ippolito GC, Fujiwara Y, Ebert BL, 
Tucker PW, Orkin SH. Correction of sickle cell disease in adult mice by interference with fetal 
hemoglobin silencing. Science. 2011 Nov 18;334(6058):993 -6. 
Sangamo Therapeutics , Inc. 
ST-400-01 CONFIDENTIAL AND P ROPRIETARY  
Page 79 of 82 © 2021, Sangamo Therapeutics, Inc  April 9th, 2021 APPENDIX 1: SCHEDULE OF EVENTS  
PRIMARY STUDY PERIODScreening
(6 weeks +/- 4 
weeks)Mobilization & 
Apheresis 
(within 1 week 
prior to first 
mobilizing agent 
administration)Baseline 
(within 2 weeks 
prior to 
conditioning)ConditioningST-400 
Infusion
(Day 0)Day 7
(+/- 1 d)Day 14
(+/- 1 d)Day 21
(+/- 1 d)Day 28
(+/- 1 d)Day 35
(+/- 2 d)Day 42
(+/- 2 d)Day 56
(+/- 5 d)Day 90
(+/- 7 d)Week 26
(+/- 14 d)Week 39
(+/- 14 d)Week 52
(+/- 14 d)ETV (s)
Informed Consent X
Medical History X
Demographics X
Inclusion/Exclusion Criteria X
Subject Number X
Transfusion History (a) X 
Concomitant Medications X (m) X (o) X X (p) X X X X X X X X X X X X X
Adverse Events X X (o) X X X X X X X X X X X X X X X
Physical Exam (b) X X (o) X X X X X X X X X X X X X X X
Vital Signs X X (o) X X X (r) X X X X X X X X X X X X
Height X
Weight X X X
Karnofsky Performance Scale X X X X X
Pregnancy Test (c) X X(o) X X X X X X X X
Pulmonary Function Tests (PFTs) X (f) X
Chest X-ray X (f)
Infectious Disease Panel X
Clinical Labs X X (o) X X (q) X X X X X X X X X X X X X
ECG X X X X X X X
Liver Biopsy (d) X
Hemoglobin Analysis X
HbF Quantification X X X X X X X X X X X X
BCL11A Gene Modification Assay X X X X X X X X X X
Thalassemia-related Disease Biomarkers (e) X X X X X X X X
Endocrine Lab Testing X X X X
ECHO X (f) X X
Liver MRI X X X
Cardiac MRI X X X
SF-36 Survey X X X X X
Transfusion Log X (o) X X X X X X X X X X X X X X X
Immunological Assays  (g) X X X X
Subset Analysis of BCL11A Gene Modification X
Sampling for Potential Retrospective Analysis in 
the Event of Hematological MalignancyX X X X X X
DXA X X
Bone Marrow Aspiration (h) X X (h) X (h) X (h) X X
% F-cells X X X X X X
Screening for Malignancy X X X X X X X X X
Gamete or Embryo CryopreservationX (approx. 30 
days prior to ST-
400 infusion)
G-CSF (n, i) X
Plerixafor (n, i) X
Collection of CD34+ HSPCs (j) X
Sangamo Therapeutics , Inc. 
ST-400-01  CONFIDENTIAL AND P ROPRIETARY  
 
Page 80 of 82                               © 2021, Sangamo Therapeutics, Inc   April 9th, 2021 
    
  Week 65  
(+/- 14 d)  Week 78  
(+/- 14 d)  Week 91  
(+/- 14 d)  Week 104  
(+/- 14 d)  Week 117  
(+/- 14 d)  Week 130  
(+/- 14 d)  Week 143  
(+/- 14 d)  Week 156  
(+/- 14 d)  
Concomitant Medications  X X X X X X X X 
Adverse Events  X X X X X X X X 
Physical Exam (b)  X X X X X X X X 
Vital Signs  X X X X X X X X 
Karnofsky Performance Scale        X       X 
Clinical Labs  X X X X X X X X 
ECG       X       X 
HbF Quantification  X X X X X X X X 
BCL11A Gene Modification Assay    X   X   X   X 
Thalassemia -related Disease Biomarkers (e)    X   X   X   X 
Endocrine Lab Testing  X       X       
ECHO (f)        X       X 
Liver MRI        X       X 
Cardiac MRI        X       X 
SF-36 Survey        X       X 
Transfusion Log  X X X X X X X X 
Immunological Assays (g ) X       X       
Subset Analysis of BCL11A Gene Modification      X       X   
Sampling for Potential Ret rospective Analysis in the Event of 
Hematological Malignancy    X   X   X   X 
DXA       X       X 
Bone Marrow Aspiration (h)        X         
Screening for Malignancy  X X X X X X X X 
(a) A minimum of 2 years of transfusion history prior to S creening is required to be eligible to participate in this study . Up to 3 years of history will be recorded if available. 
(b) A physical examination will be conducted on each subject at  the specified visits, and will include at a minimum: general appearance; head, eyes, ears, nose, and throat (HEENT); 
as well as cardiovas cular, dermatologic, respiratory, gastrointestinal, musculoskeletal, and neurologic systems.  Any clinically significant changes from previous visits or new findings 
should be documented in the source and reported as an adverse event .  
(c) For female subjects  with reproductive  potential only. Serum pregnancy testing will be c onducted at the 3 pre-infusion timepoints , and urine testing will be conducted for the 
post-infusion timepoints  with confirmation by serum testing if urine testing is posit ive or equivocal . Baseline pregnancy testing should be conducted within 1 week prior to first 
busulfan infusion . 
(d) May have been performed in prior 12 months with adequate medical documentation.  
(e) Thalassemia -related disease biom arkers may include, but are not limited to , iron metabolism , erythropoietin, haptoglobin, and hepcidin levels.  
(f) If more than 30 weeks will elapse between the start of the Screening visit and the Baseline visit, the following tests will be repeated  at Baseline: pul monary Function Tests (PFTs), 
chest X-ray, and echocardiogram (ECHO). Additional tests may be repeated as appropriate to confirm eligibility at the discretion of the Investigator.  
(g) Immunological assays include , but are not limited to , lymphocyte subsets  and quantitative immunoglobulins.  
(h) Bone marrow aspiration at the Day 90 visit may be waived at the Investigator’s discretion. Bone marrow aspirate may be performed at either the Week 26 or the Week 39 visit; 
it should not be performed at both.  Both of  these procedures  (at both Week 26 and Week 39) may be waived at the Investigator’s discretion.  Unscheduled  bone marrow aspiration 
may also be conducted at any time if clinically indicated, such as to evaluate the potential development of hematological ma lignancy. 
(i) G-CSF and plerixafor dosing, timing, or route of administration may be modified or discontinued at the discretion of the Invest igator if the WBC exceeds 100,000 cells/L or if 
the subject becomes symptomatic.   
Sangamo Therapeutics , Inc. 
ST-400-01  CONFIDENTIAL AND P ROPRIETARY  
 
Page 81 of 82                               © 2021, Sangamo Therapeutics, Inc   April 9th, 2021 
   (j) If the first apheresis cycle does not mobi lize the minimum number of CD34+ HSPCs required for ST -400 drug manufacturing and for rescue treatment, the mobilization procedure 
may be repeated. Selection of the timing of a second apheresis will be at the discretion of the Investigator based on the sub ject’s clinical status and may occur no sooner than 2 weeks 
after the initial apheresis . 
(k) Subjects will not  proceed to conditioning  procedure with IV busulfan until a sufficient quantity of res cue treatment is obtained and ST -400 is manufactured, passes  quality control 
and release testing, and is confirmed as received at the clinical site .  
(l) Dose of ST -400 will be administered IV as a single dose no sooner than 72 hours after the final dose of IV busulfan in the conditioning phase.  
(m) Any scheduled v accinations (e.g., influenza) must be compl eted at least 30 days prior to the conditioning phase . 
(n) Prior to mobilization it is recommended that subjects have a Hb level of ≥9.0 g/dL.  
(o) Conducted  within one week prior to administration of the first mobilization agent . Adverse Events assessed on each day of the visit.  
(p) Seizure prophylaxis during IV busulfan is strongly recommended. Iron -chelating agents should be discontinued 2 weeks prior to busulfan and may be restar ted after successful 
hematopoietic reconstitution or at the discretion of the Investigator. Concomitant acetaminophen or metronidazole should be a voided. Additional guidance on busulfan drug 
interactions with commonly used concomitant medications is provid ed in the Study Cell Therapy Manual . 
(q) Samples for central laboratory analysis (“Clinical laboratory tests”) should be collected at least once during conditioning, with timing at the discretion of the Investigator . 
(r) Vital signs (temperature, he art rate, respiratory rate, blood pressure , and oxygen saturation ) will be monitored before, during, and after the infusion as detailed in the Study 
Reference Manual , and as needed to maintain good clinical care in accordance with study center practice . 
(s) It is at the discretion of the Investigator, in consultation with the Medical Monitor, to waive any procedure if the procedure h as been performed within the standard interval of 
scheduled study visits.  
 
Sangamo Therapeutics , Inc. 
ST-400-01  CONFIDENTIAL AND PROPRIETARY   
Page 82 of 82 © 2021, Sangamo Therapeutics, Inc   April 9tth, 2021 APPENDIX 2 : -GLOBIN  ALLELLIC VARIANTS ASSOCIATED WITH CLINICALLY 
SIGNIFICANTLY ALTERED  OXYGEN AFFINITY  
HbF structural variants are rare. Although  some HbF variants have no clinical significance , there are 
HbF mutations that lead to unstable hemoglobin or hemoglobins with deleter iously altered oxygen 
affinity. All subjects will have sequencing of the γ-globin gene evaluated at S creening. Subjects with 
γ-globin mutations that have clinical significance are not e ligible to participate in this study.  Examples 
of known clinically-significant γ -globin variants are provided below (not inclusive list):  
• Hb F-Poole 
• Hb F-M Osaka 
• Hb F-La Grange  
• Hb F-Cincinnati  
• Large deletions such as γβ -thalassemia or εγδβ -thalassemia  
 
 